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List of abbreviations 
 
4EBP1  eukaryotic translation initiation factor 4E binding protein 1 
AKT1S1 Akt1 substrate 1 
AMPK   AMP-activated kinase 
AS160   Akt substrate of 160 kDa 
BMI  body mass index 
ERK   extracellular-signal regulated kinase 
GSK   glycogen synthase kinase 
HFD   high fat diet 
HIF1α  hypoxia-inducible factor 1α 
IRS   insulin receptor substrate 
LFD   low fat diet 
mLST8  mammalian ortholog of yeast Lethal with Sec13 protein 8 
mTOR  mammalian target of rapamycin 
mTORC  mTOR complex 
NES  nuclear export signal 
PI3K  phosphatidylinositol 3’-kinase 
PKB/Akt  protein kinase B 
PKC  protein kinase C 
PDGF   platelet-derived growth factor 
PRAS40  proline-rich Akt substrate of 40 kDa 
PRR5  proline-rich repeat protein 5 
PTEN   phosphatase and tensin homolog 
Raptor   regulatory associated protein of mTOR 
Rheb   Ras homolog-enriched in brain 
Rictor   rapamycin-insensitive companion of mTOR 
S6K  p70 S6 kinase 
SGK   serum- and glucocorticoid-regulated kinase 
T2DM   type 2 diabetes mellitus 
TBC1D4  TBC1 domain family member 4 
TOS   mTOR signalling motif 
TSC   tuberous sclerosis complex 
YY1  yin yang 1 




































Diabetes is taking on epidemic proportions not only in western society. According to the 
World Health Organization more than 180 million cases of diabetes have been reported and 
as an estimate for the coming years, the number of people with diabetes will be over 375 
million by the year 2030. A deeper understanding of diabetes is thus required in order to 
device better treatment strategies or to even prevent the onset of diabetes. In this general 
introduction, an overview is provided explaining how normal glucose homeostasis is 
accomplished through the metabolic action of insulin and how deregulation of insulin 
action can result in insulin resistance and diabetes. Special attention will be focused on 




All living cells use glucose as main or only source of energy. Maintenance of physiological 
glucose levels is thus essential for proper energy homeostasis. Breakdown of glucose via 
glycolysis to acetyl groups yields ATP. Subsequently, the remaining acetyl group is 
degraded by the Krebs cycle to CO2 and NADH and FADH2. Oxidation of the latter 
components by the mitochondrial respiratory chain yields additional ATP. Normal plasma 
glucose levels are maintained at 5 mM in the fasting state in an average adult human being. 
Regulation of glucose levels is tightly regulated by glucose itself and through stimulation of 
insulin secretion. It was in 1921 that Canadian scientists and Nobel price winners Frederick 
G. Banting and Charles H. Best successfully purified insulin from the pancreas and were 






































Figure 1. Overview of the human proinsulin precursor molecule. The A- and B-chain are linked together by 
disulfide bonds after removal of the C-peptide and signal peptide.  
 
The peptide hormone insulin (5.8 kDa) is produced in the islet of Langerhans by the β-cells. 
The name for insulin is derived from the latin word “insula” which means island. Insulin is 
synthesized from the proinsulin precursor molecule (Fig. 1). After removal of signal 
peptide and the C-peptide, the A- and B-chain are linked together by disulfide bonds. In 
general insulin induces an anabolic effect in cells and tissues. More specifically the effects 
of insulin include glucose uptake by muscle and adipose tissue, decrease of hepatic glucose 
production (gluconeogenesis), stimulation of cell growth and differentiation, storage of 
substrates in adipose tissue, liver and muscle (lipogenesis, glycogen and protein synthesis, 
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inhibition of lipolysis, glycogenolysis and protein breakdown), increased fatty acid 
synthesis and esterfication of fatty acids, increased amino acid uptake and vasodilatation 
(relaxation of vessel wall of blood arteries, allowing for more blood flow). Glucagon which 
is produced in the α-cells of the pancreas counteracts some of the metabolic effects of 
insulin. Glucagon as catabolic hormone and insulin as anabolic hormone are together able 
to regulate normal plasma glucose levels.  
 
Insulin release is accomplished when blood glucose levels are increased. As a result, more 
glucose is taken up by the β-cell via glucose transporter GLUT2 and action of glucokinase. 
This results in an enhanced flux through the subsequent glycolytic pathway and citric acid  
cycle resulting in an increased ATP/ADP ratio. As a result the ATP-sensitive potassium 
(K+) channels close, causing the cell membrane to depolarize. Depolarization of the cell 
membrane results in the opening of the voltage controlled calcium (Ca2+) channels, 
allowing an influx of calcium. The increase of intercellular Ca2+ releases insulin from the 
stored vesicles (Fig. 2). By this mechanism, glucose levels are tightly regulated. 
 
 
Figure 2. The process of glucose dependent insulin secretion from the pancreatic β-cell. The key players in insulin 
secretion from the β-cell are glucose transporter GLUT2, glucokinase, ATP-sensitive potassium (K+) channel and 



















Disturbance in glucose homeostasis: Diabetes mellitus 
Diabetes is a disease state in which glucose concentrations in blood are chronically elevated 
(hyperglycaemia). Diabetes develops when the amount of secreted insulin by β-cells is 
insufficient for insulin action. The latter is dependent on the degree of insulin resistance in 
various insulin sensitive tissues. Different forms of diabetes have been identified. In type 1 
diabetes mellitus (T1DM), the β-cells are destroyed causing an absolute insulin deficiency, 
resulting in hyperglycaemia. T1DM manifests itself around puberty. In case of type 2 
diabetes mellitus (T2DM), a patient is still able to produce insulin, however the secreted 
amounts are not sufficient to lower blood glucose levels to the appropriate physiological 
level because the major target organs for insulin action (liver, skeletal muscle and adipose 
tissue) are unable to fully respond to insulin. The latter condition is thus called insulin 
resistance. Onset of T2DM is at a much later stage in life, however this phenomenon is 
currently also affecting (obese) youngsters. The acute complications arising from a total 
absence of insulin, as seen in T1DM, are hyperglycaemia, ketoacidosis and nonketotic 
hyperosmolar coma. Untreated long term hyperglycaemia induces microvascular damage, 
leading to blindness and kidney failure. Furthermore, it induces damage to the long sensory 
nerves resulting in foot problems. In addition, the insulin resistant state as seen in T2DM is 
a major risk factor for macrovascular complications, increasing death risk due to 
cardiovascular problems. Treatment of T1DM involves supplementation with insulin by 
injection, while treatment of T2DM can be controlled by dietary change, medication or 
injections with insulin depending on the severity. Other types of diabetes have been 
described. During pregnancy, women can develop diabetes which resembles very much to 
T2DM and is therefore called gestational diabetes. Many of these women develop T2DM 
later in life. A mutation in a single gene is can also be sufficient to give rise to diabetes eg. 
Maturity Onset Diabetes of the Young (MODY) (1-4) and Maternally Inherited Diabetes 
and Deafness (MIDD) (5). Latent Autoimmune Diabetes in Adults (LADA) is a form of 
T1DM which progresses very slowly, thus causing confusion with T2DM. The distinction 
between LADA and T2DM can be made, since in LADA antibodies against glutamatic acid 
carboxylase are present (6).  
 
Downstream signal transduction from the insulin receptor 
In order to better understand how insulin action is accomplished and how insulin action is 
altered under the insulin resistant state, a deeper understanding of insulin signalling is 
required. Insulin induces multiple responses (both mitogenic and metabolic) and often the 
nature of these response is tissue specific. Downstream signalling described below is 
generally linked to the metabolic effects of insulin. However how different signalling 
intermediates are able to contribute to the various insulin-stimulated responses is far from 
complete. The very first step in insulin action is accomplished by binding of insulin to its 
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corresponding receptor. Binding results in the activation of a downstream signalling 
cascade which starts at the insulin receptor.  
 
Insulin receptor The insulin receptor (IR) is part of a subfamily of receptor tyrosine 
kinases which include the insulin receptor-related receptor (IRR) and the insulin-like 
growth factor (IGF)-I receptor. The receptor is made up out of two extracellular α-subunits 
and two transmembrane β-subunits resulting in a α2β2 heterotetrameric complex which are 
joined by disulfide bonds. The α-subunit is able to inhibit the tyrosine kinase activity of the 
β-subunit. Thus binding of insulin to the α-subunit actives the tyrosine kinase of the β-
subunit. The receptor undergoes a series of intramolecular transphosphorylation reactions in 
which one β-subunit phosphorylates its adjacent partner on specific tyrosine residues.  
 
The activated IR is now able to phosphorylate tyrosine residues on intracellular substrates 
that include member of the insulin receptor substrate family (IRS1-6 (7-11)), Grb2-
associated binder-1 (Gab-1 (12)), Cas-Br-M (murine) ecotropic retroviral transformin 
sequence homologue (Cbl (13)), adaptor containing PH and SH2 domains (APS (14)), Src 
homology 2 contaning protein (Shc (15)) and signal regulatory protein (SIRP) family 
members. IRS and Shc are recruited to the juxtamembrane region via a common NPXY 
motif, while APS is able to directly bind to the activation loop. The phosphotyrosine 
residues are recognized by molecules which contain Src homology 2 (SH2) domains like 
small adaptor proteins Gbr2 and Nck, the SHP2 protein tysoine phosphatise and the p85 
regulatory subunit of the class IA phosphatidylinositol 3’-kinase (PI3K).  
 
Phosphatidyl inositol 3’-kinase (PI3K) The PI3K enzyme is composed out of a regulatory 
and a catalytic unit. The PI3K family is composed of class IA, class IB, class II and class III 
and the various classes display different substrate specificity. The class IA is the most 
important with respect to metabolic action after binding of insulin to the IR and is 
composed of p110α catalytic subunit and its associated regulatory subunit p85. Binding of 
p85 to p110α stabilizes p110α and thus inactivates its kinase activity. Upon stimulation, 
p110α is not inhibited by p85 leaving kinase activity of p110α uninhibited (16). At the 
plasma membrane, PI3K phosphorylates phosphoinositides on the 3’-OH (D3) position of 
the inositol ring to generate second messengers phosphatidylinositol-3,4-bisphosphate (PI-
3,4-P2) and phosphatidylinositol-3,4,5-triphosphate (PIP3) from substrates 
phosphatidylinositol-4-phosphate (PI-4-P) and phosphatidylinositol-4,5-bisphosphate 
(PIP2). Phosphatase and tensin homolog (PTEN) dephosphorylates the 3’-OH position of 
the inositol ring, acting as a suppressor to PI3K. Proteins with a Pleckstrin homology (PH) 
domain can bind and localize to the lipid second messenger PIP3 (review in (17)). The AGC 
kinase 3-phosphoinositide-dependent protein kinase 1 (PDK1) and downstream 
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phosphorylation substrate protein kinase B (PKB/Akt) are both recruited to the plasma 
membrane via their PH domain (Fig. 3).  
 
 
Figure 3. Activation of protein kinase B (PKB/Akt) after insulin binding to the insulin receptor. For detailed 
description see text.  
 
Protein kinase B (PKB/Akt) The Ser/Thr kinase protein kinase B is composed of a N-
terminal PH domain, a C-terminal catalytic domain and a hydrophobic motif and is highly 
conserved among different species (18). Generated PIP3 is able to recruit PKB/Akt via its 
PH domain to the plasma membrane. For full potential of PKB/Akt, phosphorylation occurs 
at two different residues; phosphorylation of Thr308 in the catalytic domain occurs via 
PDK1 and phosphorylation of Ser473 in the hydrophobic motif site occurs via PDK2 
(mTORC2 (19;20)). Once phosphorylated, PKB/AKT dissociates from the membrane and 
is able to phosphorylate targets in the cytoplasm and the cell nucleus (Fig. 4). In mammals 
three genes encode for the PKB/Akt family: Akt1 (PKBα/Akt1), Akt2 (PKBβ/Akt2) and 
Akt3 (PKBγ/Akt3). The isoforms are products from distinct genes and overall they share a 
high degree of amino acid identity (>80%). PKBα/Akt1 and PKBβ/Akt2 are expressed 
ubiquitously, while expression of PKBγ/Akt3 is highest in brain and testes. Studies from 
knockout animals demonstrate that PKB/Akt is important in development and (glucose) 
metabolism. Akt1-/- mice are smaller compared to their wild type littermates and male  
Akt1-/- mice have increased apoptosis in the testes. Mouse embryonic fibroblasts from  
Akt1-/- mice are more sensitive to apoptotic stimuli (21). Akt2-/- mice are both 
hyperglycaemic and hyperinsulinaemic (22). Akt3-/- mice have smaller brains compared to 
wild type animals (23;24). All single knockout animals are viable indicating that PKB/Akt 
isoforms can probably compensate for the lack of another. The double knockout for Akt1 
and Akt2 has a severe phenotype which includes atrophy of skin and skeletal muscle, 
dwarfism and early neonatal lethality (25). Double knockout for Akt2 and Akt3 results in 




















































testes (26). Considering the different phenotypes of the knockout mice, PKB/Akt signalling 
has been linked to malignancies, insulin resistance/diabetes, muscle atrophy, Alzheimer 
disease and chronic obstruct pulmonary disease (27-33).  
 
PKB/Akt and PKB/Akt substrates in cellular processes and disease 
PKB/Akt is protein kinase able to regulate a wide range of cellular processes: (glucose) 
metabolism, apoptosis, proliferation and angiogenesis. In order to achieve these effects 
different PKB/Akt substrates have been identified and linked to these processes. PKB/Akt 
specifically phosphorylates substrates that contain the following amino acid motif: Arg-
Xaa-Arg-Xaa-Xaa-pSer/pThr (34;35). The number of substrates is ever increasing and a 
combined search of “protein kinase B”, "phosphorylation” and “substrate” in Pubmed 
results in over 1500 hits.  
The tuberous sclerosis complex (TSC) is a downstream phosphorylation target of PKB/Akt. 
Phosphorylation of TSC2 by PKB/Akt results in an inhibition of TSC activity (36). As a 
result, Ras homolog-enriched in the brain (Rheb)-GDP is converted into Rheb-GTP, thus 
allowing Rheb-GTP to activate mammalian target of rapamycin (mTOR) (37;38). mTOR is 
a component of two distinct complex called mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). The mTORC1 complex is sensitive for mTOR inhibitor rapamycin, 
while mTORC2 is not. mTORC1 is composed out of mTOR, regulatory associated protein 
of mTOR (Raptor), mammalian LST8/G-protein β-subunit like protein (mLST8/GβL) and 
proline-rich PKB/Akt substrate of 40 kDa (PRAS40) (39;40). Direct substrates for 
mTORC1 include p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding 
protein-1 (4EBP1). Via this way mTORC1 is able to regulate protein synthesis.  
With respect to metabolism PKB/Akt is able to phosphorylate glycogen synthase kinase 
(GSK) which results in the downstream phosphorylation and inactivation of glycogen 
synthase (41). Via phosphorylation of PKB/Akt substrate of 160 kDa (AS160), PKB/Akt is 
able to regulate GLUT4 mediated glucose uptake (42). The forkhead box O (FOXO) 
transcription factors play an important role as PKB/Akt substrates controlling gene 
expression. Nuclear exclusion of FOXO inhibits gluconeogenesis while promoting β-cell 
function (43;44). FOXO proteins exert many different functions and are also able to 
regulate expression of Bcl2 family members thereby regulating apoptosis (review in (45)).  
Involvement of PKB/Akt in the process of programmed cell death or apoptosis can be 
mediated by phosphorylation and inhibition of pro apoptotic mediators such as Bad, 
MDM2 (46), FOXO and IκΒ kinase (IKK (47)). When dephosphorylated, Bcl2 family 
member Bad is able to complex with BclXL resulting in apoptosis. However 




In cell cycle control, PKB/Akt can phosphorylate cyclin-dependent kinase (CDK) inhibitors 
p21CIP1/WAF1 (49) and p27KIP1 (50) which results in the cytoplasmic retention of these 
proteins, since they are able to bind 14-3-3. PKB/Akt is thus able through p21CIP/WAF1 able 
to inhibit cell cycle arrest.  
The list of identified PKB/Akt phosphorylation substrates is always increasing of which a 
small sample is included in the following list: ATP-citrate lyase (51), WNK1 (52), NDRG2 
(53), PRAS40 (54), Synip (55), filamin C (56), JCF1 (57), VCP (58-60), PIKfyve (61), 
YB1 (62;63), Par-4 (64). However from the more recent PKB/Akt substrates it not always 
clear in which cellular processes they play a role.  
 
Rationale and outline of thesis 
Impairment of glucose metabolism is associated with decreased activity of PI3K and 
downstream signalling partner PKB/Akt. The PI3K and PKB/Akt signalling pathway is 
able to exert numerous different effects mediated through specific PKB/Akt substrates. A 
lot of distinct functions can be described to PKB/Akt substrates, however from a lot 
PKB/Akt substrates it remains unclear what their specific function is. Therefore in this 
thesis, the focus is on PKB/Akt substrate PRAS40 and examine how phosphorylation of 
this substrate is altered under conditions of insulin resistance. Next we examine the 
function of PRAS40 in respect to insulin action. In chapter 2, an overview is provided on 
different literature concerning PRAS40. Special attention will be paid to PRAS40 and the 
role of this protein in the regulation of mTORC1. In chapter 3, phosphorylation of 
PRAS40 on Thr246 both in vitro and in vivo is examined. Using an animal model for 
insulin resistance we have assessed phosphorylation status of PRAS40 under insulin 
resistance. Chapter 4 describes phosphorylation of PRAS40 on Ser183 and the importance 
of Thr246 in this process. Chapter 5 describes the subcellular localisation of the PRAS40 
protein. In chapter 6, we investigate the involvement of PRAS40 in palmitate-induced 
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Alterations in signalling via protein kinase B (PKB/Akt) and the mammalian target of 
rapamycin (mTOR) frequently occur in type 2 diabetes and various human malignancies. 
Proline-rich Akt substrate of 40 kDa (PRAS40) has a regulatory function at the intersection 
of these pathways. The interaction of PRAS40 with the mTOR complex 1 (mTORC1) 
inhibits the activity of mTORC1. Phosphorylation of PRAS40 by PKB/Akt and mTORC1 
disrupts the binding between mTORC1 and PRAS40, and relieves the inhibitory constraint 
of PRAS40 on mTORC1 activity. This review summarizes the signalling pathways 
regulating PRAS40 phosphorylation, as well as the dual function of PRAS40 as substrate 
and inhibitor of mTORC1 in the physiological situation, and under pathological conditions, 




Proline-rich PKB/Akt substrate of 40 kDa (PRAS40) is a component of the mammalian 
target of rapamycin complex (mTORC) 1 (1-4). The catalytic subunit of mTORC1, 
mammalian target of rapamycin (mTOR), is shared with another multimeric protein 
complex, termed mTORC2. In addition to mTOR and PRAS40, mTORC1 consists of the 
regulatory associated protein of mTOR (raptor), and the mammalian ortholog of yeast 
Lethal with Sec13 protein 8 (mLST8, also known as Gβ1) (5-8). Signalling by mTORC1 is 
sensitive to rapamycin and regulates multiple cellular processes, such as mRNA translation, 
ribosome biogenesis, cell cycle progression, hypoxia, autophagy, mitochondrial function, 
lipid storage, and chronological lifespan through phosphorylation of multiple substrates (for 
review see (9-11)). The growing list of mTORC1-regulated proteins includes yin yang 1 
(YY1), signal transducer and activator of transcription 3 (STAT3), serum- and 
glucocorticoid regulated kinase 1 (SGK1), PRAS40, phospholipase D2 (PLD2), hypoxia-
inducible factor 1α (HIF1α), and Akt substrate of 160 kDa (AS160, also known as TBC1 
domain family member D4 (TBC1D4)), in addition to the well characterized substrates,  
eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and the p70 S6 kinases 
(S6K1 and S6K2) (12-22) (Table 1).  
The mTORC2 complex contains mTOR, rapamycin-insensitive companion of mTOR 
(rictor), mSin1, mLST8, and proline-rich repeat protein-5 (PRR5, also known as protor) or 
PRR5-like (2;23-29). Active mTORC2 not only regulates actin polymerisation, but also 
promotes phosphorylation of the hydrophobic motifs of protein kinase B (PKB/Akt), and 
SGK1. Also phosphorylation of both the turn- and hydrophobic motifs within the protein 
kinase C (PKC) α isoform, and likely also within the PKC βI, βII, γ, and ε isoforms is 




















Table 1. Overview of substrates for mTORC1 and mTORC2 
 
 
Phosphorylation site TOS motif RAIP motif 
mTORC1-regulated proteins:  
4EBP1, 2, 3 Thr37, Thr46, Ser65, Thr70 FEMDI RAIP 
HIF1α  FVMVL  
PLD2  FEVQV  
PRAS40 Ser183, Ser212, Ser221 FVMDE KSLP 
S6K1 Thr389 FDIDL  
S6K2 Thr388 FDLDL  
SGK1 Ser422   
STAT3 Ser727 FPMEL RAIL 
TBC1D4 Ser666 FEMDI  
YY1    
mTORC2-regulated proteins: 
PKB/Akt Ser473 n.a. n.a 
PKCα Thr638, Ser657 n.a n.a 
PKCβ1  n.a n.a 
PKCβ2  n.a n.a 
PKCγ  n.a n.a 
PKCε  n.a n.a 
SGK1 Ser422 n.a n.a 
 
mTOR and disease 
 
Type 2 diabetes. Clinical insulin resistance of peripheral target tissues for insulin action, 
like the liver, skeletal muscle and adipose tissue, in combination with insufficient 
compensatory insulin secretion by the β-cells in the islets of Langerhans characterizes type 
2 diabetes (T2D) (37). At the molecular level, both insulin resistance and T2D are often 
associated with an impaired activation of phosphatidylinositol 3’-kinase (PI3K) and its 
substrate PKB/Akt after insulin stimulation (38). In the liver, skeletal muscle, heart, and 
adipose tissue, the PI3K-PKB/Akt pathway regulates glucose metabolism (39;40). In the 
pancreas, the PI3K-PKB/Akt pathway promotes β-cell growth, proliferation, and survival 
(41). Activation of the PI3K-PKB/Akt pathway by insulin is mediated by recruitement of 
PI3K to the tyrosine phosphorylated insulin receptor substrates (IRS) 1 and 2 (42;43). 
Conversely, the induction of tyrosine phosphorylation of IRS1/2 is blunted upon serine 
phosphorylation of IRS1/2 (44-49). Serine phosphorylation of the IRS-proteins not only 
reduces the activation of the PI3K-PKB/Akt pathway by insulin, but also leads to 
proteasome-mediated protein degradation of IRS1/2 through interaction with 14-3-3 
proteins (50-53).  
Several studies on high-fat diet fat rodents show elevated activity of the mTORC1 
signalling pathway (54-57). The sustained activity of S6K1 may abrogate insulin-mediated 
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activation of the PI3K-PKB/Akt pathway by inducing inhibitory serine phosphorylations on 
the insulin receptor and IRS1/2 (58-62). Accordingly, genetic ablation of S6K1 (63), or 
lowering mTORC1 activity with rapamycin (64) or chronic exercise (65) reduces IRS1 
serine phosphorylation and reverses the inhibition of the PI3K-PKB/Akt pathway in the 
liver, skeletal muscle, and adipose tissue. In contrast, rapamycin treatment does not 
improve insulin sensitivity in ob/ob mice (66), indicating that rapamycin-insensitive protein 
kinases, such as c-jun N terminal kinase, inhibitor of kappa B kinase and PKC isoforms, 
might contribute to inhibition of insulin signalling (67). Alternatively, mTORC1 action 
may differ between tissues. For example, mTORC1 regulates mitochondrial function via 
the transcriptional regulators YY1 and PGC1α in skeletal muscle (68), and is crucial for β-
cell survival and insulin biosynthesis in the pancreas (69-74). Recently, the tissue-specific 
regulation of metabolic control by mTORC1 has been reviewed extensively (75;76). 
 
Cancer. Multiple human malignancies and inherited hamartoma syndromes show increased 
activity of mTOR (77-79). As will be described in more detail under “Regulation of 
mTORC1 activity”, the tuberous sclerosis complex (TSC), a GTPase activating protein 
complex consisting of two subunits, TSC1 (also known as hamartin) and TSC2 (also known 
as tuberin) is a key upstream regulator of mTORC1 (reviewed by (80)). Various protein 
kinases, including PKB/Akt, AMP-activated kinase (AMPK), and extracellular-signal 
regulated kinase (ERK), affect the activity of TSC via phosphorylation of the TSC2 (81-
84). In particular, hyperactivation of PKB/Akt is a common characteristic of human 
malignancies (85;86). Since PKB/Akt activates mTORC1 by phosphorylating TSC2 and 
mTORC2 acts a upstream activator of PKB/Akt, mTOR may function both upstream and 
downstream of PKB/Akt in the pathogenesis of human cancer as has been extensively 
reviewed by others (87-91).  
The hamartoma syndrome tuberous sclerosis is characterized by inactivating mutations in 
TSC1 (92) or TSC2 (93). Other hamartoma syndromes have been linked to loss of function 
of tumour suppressors that regulate TSC activity (94;95). The Cowden syndrome can be 
ascribed to a loss of function of phosphatase and tensin homolog (PTEN), a phosphatase 
inactivating PI3K, the upstream regulator of PKB/Akt (for review see (96)). Inactivating 
mutations in LKB1, the upstream regulator of AMPK, underlie the Peutz-Jeghers syndrome 
(97;98). Finally, mutations in the neurofibromanin gene which encodes a GTPase activating 
protein for Ras, cause neurofibromatosis type 1 (99). The NF1 mutation results in high 
intracellular levels of active Ras that inactivate TSC2 through sustained activation of two 






Regulation of mTORC1 activity 
As summarized in Figure 1, activation of mTORC1 in response to anabolic stimuli, such as 
insulin and nutrients, like amino acids and glucose, involves the integration of multiple 
signalling pathways at the level of mTORC1 (101;102). Activation of the mTOR protein 
kinase occurs via binding of the GTP-bound form of the small GTP-binding protein Ras 
homolog-enriched in brain (Rheb) (103). To bring mTORC1 in the proximity of Rheb, 
amino acids are required (104). Amino acids increase the intracellular RagA- and RagB-
GTP levels, thereby stimulating the binding of these small GTPases to raptor (105;106). 
The binding of the Rags serves to relocate mTORC1 to Rheb-containing peri-nuclear 
vesicular structures, thus allowing mTOR to interact with Rheb (107). The levels of GTP-
bound Rheb are regulated by TSC, which acts as a GTPase activating protein on Rheb 
(108). Insulin inhibits TSC activity through PKB/Akt-mediated phosphorylation of TSC2 
(109;110). As a result, Rheb is relieved from the inhibitory GTPase activity, thus allowing 
Rheb-GTP to bind and activate mTORC1. Glucose activates mTORC1 by inhibiting 
AMPK (111-113). AMPK, when activated such as in response to energy deprivation, 
activates TSC2 (114), thus promoting the hydrolysis of Rheb-GTP and inhibition of 
mTORC1.  
Figure 1. Regulation of mTORC1 activity 
by insulin, amino acids, glucose and 
energy deprivation. The activation of 
mTORC1 requires the binding of the small 
GTP-binding protein Rag and Rheb to 
mTORC1. The levels of GTP-bound Rag 
are enhanced by amino acids. Inhibition of 
the activity of TSC1/TSC2 complex 
increases cellular Rheb-GTP-levels. TSC2 
is regulated by phosphorylation. AMPK-
mediated phosphorylation of TSC2 leads to 
activation of TSC2 and inactivation of 
mTORC1. Phosphorylation of PKB/Akt on 
its turn inactivates TSC2, thus increasing 
Rheb-GTP levels. Full activation of 
mTORC1 further requires the dissociation 
of PRAS40 from mTORC1, which requires 
phosphorylation of PRAS40 by both 
PKB/Akt and mTORC1. When activated, 
mTORC1 regulates protein synthesis and 
cellular growth through phosphorylation of 
S6K1 and 4EBP1. Furthermore, the 
activated S6K1 exerts a negative feedback 
loop on IRS1 thereby blunting insulin-


































Identification of PRAS40. PRAS40 was originally described as a 40 kDa protein that binds 
to 14-3-3 proteins in lysates from insulin-treated hepatoma cells (115). PRAS40 is probably 
identical to the p39 protein that is phosphorylated in PC12 cells in response to nerve growth 
factor or epidermal growth factor (116). Finally, PRAS40 has been described as Akt1 
substrate 1 (Akt1S1), a phosphoprotein identified from nuclear extracts from Hela cells 
(117). 
PRAS40 was recognized as component of the mTORC1 complex following mass 
spectrometry analysis of mTOR immunoprecipitates (2;118-120). Subsequent western blot 
studies showed that PRAS40 preferentially interacts with raptor, but that it also binds to the 
kinase domain of mTOR (2;121-123). Compared to intact mTOR, PRAS40-binding to a 
kinase-dead mutant of mTOR is reduced (2). PRAS40 has not been found in rictor 
immunoprecipitates, indicating that PRAS40 is a component of mTORC1, and not of 
mTORC2 (2;124-126).  
 
Structure and post-translational modification of PRAS40. The gene for PRAS40 is 
located on human chromosome 19q13.33 and encodes 3 transcript variants that differ in 
their 5’-UTR but result in the same 256 amino acid protein. Analysis of human, rat and 
mouse tissues demonstrates a ubiquitous expression of both PRAS40 mRNA and protein, 
with highest transcript levels found in human liver and heart (127;128). As shown in Figure 
2A, the PRAS40 protein consists of two proline-enriched stretches at the aminoterminus 
with an as yet unknown function (129), but containing sequences that have the potential to 
bind proteins containing SH3- and/or WW-domains (130). The proline-rich region is 
followed by two short sequences that have been implicated mTORC1-binding and 
phosphorylation of mTORC1 substrates, i.e. an mTOR signalling- (TOS) and a potential 
RAIP-motif (131-133). The TOS motif is located between amino acids 129 and 133 (134-
136), and is a common feature shared with multiple other mTORC1 substrates (Table 1). 
The Lys-Ser-Leu-Pro sequence located between amino acids 182 and 185 is similar to the 
RAIP-motif, which has been named after a short amino acid sequence identified in 4EBP1, 
Arg-Ala-Ile-Pro (137;138) (Table 1). The carboxyterminus of PRAS40 contains a sequence 
that matches the consensus for a leucine-enriched nuclear export sequence (NES), Leu-
xx(x)-[Leu,Ile,Val,Phe,Met]-xx(x)-Leu-x-[Leu,Ile] (139). Finally, multiple residues within 
PRAS40 can become phosphorylated, including Ser183, Ser202, Ser203, Ser212, Ser221, 
and Thr246 (140-142) (Figure 2A). 
Highly conserved homologues of PRAS40 have been identified down through Danio rerio. 
PRAS40 homologues almost identical to the human protein have been found in Bos taurus, 
Mus musculus, and Rattus norvegicus. The homologues from Xenopus laevis and Danio 
rerio completely lack the proline-enriched stretches at the aminoterminus, but are 60% and 
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44% identical to the carboxyterminal part of the human protein (143), and show 
conservation of the TOS, RAIP, and NES-motifs as well as the phosphorylation sites on 
Ser183, Ser221, and Thr246 (Figure 2B). The carboxyterminal part of PRAS40 also shows 
58% and 46% similarity with the carboxyterminal part of the Lobe proteins from Apis 
mellifera and Drosophila melanogaster (144). The Lobe proteins lack the TOS motif and 
show less conservation of the NES. However, the RAIP motif as well as the equivalents of 
Ser183, Ser221, and Thr246 are preserved (Figure 2B). Human PRAS40 also has been 
reported to share some similarity with dauer or aging overexpression family member 5 
(dao-5) from Caenorhabditis elegans and Caenorhabditis briggsae (145). However, dao-5 
seems to lack preservation of the important regulatory motifs found in PRAS40 from higher 
organisms. Therefore, it remains unclear whether PRAS40 is also found in these lower 
eukaryotes. 
 
Interaction with raptor. PRAS40 binds to the mTORC1 complex predominantly through 
interaction with raptor, and dissociates in response to the addition of insulin or amino acids 
(146-150). The interaction of PRAS40 with raptor requires an intact TOS-motif, as 
mutation of Phe129 to Ala greatly reduces the binding of PRAS40 to raptor (151-153). In 
addition to the TOS-motif, the binding of PRAS40 to raptor was found to require a 
sequence located between amino acids 150 and 234 of PRAS40 (154). Some studies have 
proposed a regulatory role for the RAIP motif of PRAS40. Mutation of Ser183 or Pro185 to 
Ala reduced the PRAS40-raptor complex formation (155), and substitution of Ser183 by 
Asp completely abrogated the interaction between PRAS40 and raptor (156). In 4EBP1, the 
RAIP-motif not only directs interaction with raptor, but also is critical for mTORC1-
dependent phosphorylation of the protein (157-159). However, insulin and amino acids 
failed to promote phosphorylation of a mutant 4EBP1 in which the RAIP motif was 
replaced by the Lys-Ser-Leu-Pro sequence of PRAS40 (160). Thus, whereas 
phosphorylation of Ser183 seems to contribute disruption of the PRAS40-raptor complex 
(161;162), the function of the RAIP motif in the binding of PRAS40 to raptor still requires 




Figure 2. A. Primary structure 
of the human PRAS40 protein. 
PRAS40 consists two proline-
rich stretches followed by a 
TOS-motif, a RAIP-motif and a 
nuclear export sequence. The 
arrows indicate the sites in 
PRAS40 that can be modified 
through phosphorylation by 
PKB/Akt, mTORC1, and as yet 
unidentified protein kinases. B. 
ClustalW alignment of the 
carboxyterminal part of the 
human PRAS40 protein (amino 
acids 101-256; NP_115751) 
with the PRAS40 homologues of 
Bos taurus (NP_001076903), 
Mus musculus (NP_080546), 
Rattus norvegicus 
(NP_001099729), Xenopus 
laevis (NP_001084778), Danio 
rerio (XP_692511), Apis 
mellifera (XP_623909) and 
Drosophila melanogaster 
(NP_524787). The amino acids 
comprising the TOS-motif, the 
RAIP-motif, the NES and the 
phosphorylation sites are 
depicted in bold and underlined. 
 
Subcellular localization of PRAS40. Although PRAS40 is part of the mTORC1 complex, 
which exerts its action predominantly in the cytosol, multiple components and regulators of 
mTORC1 signalling, including PI3K, Akt, TSC2, mTOR, raptor, and S6K, are found both 
in the cytoplasm and the nucleus (163-168). The presence of a NES in PRAS40 (Figure 2) 
suggests that shuttling of the protein may occur between the cytosolic compartment and the 
nucleus. Indeed, multiple studies report a nuclear localization of the protein. Notably, 
PRAS40 has been purified as nuclear phosphoprotein from Hela cells (169). Furthermore, 
staining A14 fibroblasts and E2 H9c2 cardiomyocytes with antibodies recognizing PRAS40 
phosphorylated on Thr246 demonstrate a nuclear immunoreactivity that is promoted by 
insulin (170). Finally, immunohistochemistry studies on rat liver and heart, and mouse 
brain also demonstrate a predominant nuclear localization of Thr246-phosphorylated 







Pro-rich TOS RAIP NES
mTORC1 PKB/Akt
Pro-rich
35 43 77 96 133129 182 185
PRAS40
S202/3
H.sapiens           EDNEEDEDEP-TETETSGEQLGISDNGGLFVMDEDATLQDLPPFC---------ESDPE- 149
B.taurus            EEDEEDEDEP-TETETSGERLGVSDNGGLFVMDEDTTLQDLPPFC---------ESDPE- 149
M.musculus          EDEEEDEDEP-TETETSGERLGGSDNGGLFMMDEDATLQDLPPFC---------ESDPE- 150
R.norvegicus        EEDEEDEDEP-TETETSGERLGGSDNGGLFMMDEDATLQDLPPFC---------ESDPE- 150
X.laevis            APDEEDYDDYNKHLEKTAEHIP-SDATGLFVMDEDSNSQDCEPFF---------ESDQEE 182
D.rerio             DLEEEDEDDE--EEDLDGRRRNLNESAGVFSMDEDSLSRDCEPFF---------ESDGEE 243
A.mellifera         ANSNVKHETGAKYSSNPLINGSIDKKDRIYIYTKEPTSFDTEALFPLEGMEDTLNADQVQ 301
D.melanogaster      DADDCLFDLEDVDAPVPVQSVPVPSYTRSLIYQQQPQHNPFQQLSQQNGLRSVLDDEAAD 463
H.sapiens           STDDGSLSEETPAGPP--TCSVPPASALPTQQYAKSLPVSVPVWGFKEKRTEARSSDEEN 207
B.taurus            STDDGSLSEETPAGPP--AYSVPPASALPTQQYAKSLPVSVPVWAFKEKRTEARSSDEEN 207
M.musculus          STDDGSLSEETPAGPT--ACPQPPATALPTQQYAKSLPVSVPVWAFKEKRTEARSSDEEN 208
R.norvegicus        STDDGSLSEETPAGPP--AYPKLPATALPTQQYAKSLPVSVPVWAFKEKRTEARSSDEEN 208
X.laevis            STDDGSLTDDLPG-------HLPPQRNY--QQYAKSLPVTVPVWSFKEKRQQNKCSNDET 233
D.rerio             ESTDGSLSEEAPPPPRGMAMGHLASRSSNPMSMARSLPVSVPVWGYRNNHAPQGDSHSGE 303
A.mellifera         SSEEGSDTDDSGQDEG---IHMPRGQRGGHPTLAKSLPVSVPSFPSFVRRTVQ-DQDDDQ 357
D.melanogaster      EAEDALDPDSSISIPVR---GGGRPSHAQLMNFARSLPIEIANTTLAERAAVANNNNFGQ 520
H.sapiens           GPPSSPDLDRIAASMRALVLREAED-TQVFGDLPRPRLNTSDFQKLKRKY 256
B.taurus            GPPSSPDLDRIAASMRALVLREAED-TQVFGDLPRPRLNTSDFQKLKRKY 256
M.musculus          GPPSSPDLDRIAASMRALVLREAED-TQVFGDLPRPRLNTSDFQKLKRKY 257
R.norvegicus        GPPSSPDLDRIAASMRALVLREAED-NQVFGDLPRPRLNTSDFQKLKRKY 257
X.laevis            SKFPSPDLDRIAASMRALTIDHS----QPFGDLPRPRLNTGDFQTKYRKY 279
D.rerio             -RVGCADLDHIAASMKALLVPGATDGTEMFGALPRPRLNTGDFSLKH--- 349
A.mellifera         LSRDPHDPHNIRASIKALAKSVHGD--TVFGDLPRPRFSTQI-------- 397







Regulation of PRAS40 phosphorylation 
PRAS40 is phosphorylated on multiple sites in response to treatment of cells with growth 
factors like platelet-derived growth factor (PDGF), nerve growth factor (NGF), and insulin, 
as well as nutrients, such as glucose and amino acids (174-178). In vivo studies confirm 
PRAS40 as a physiological target for insulin action in human skeletal muscle and various 
rodent tissues, including skeletal muscle, adipose tissue, the liver, the heart and the arcuate 
nucleus (179;180) (EBMN and DMO, unpublished observations). Phosphorylation of 
PRAS40 induces 14-3-3 binding (181;182), and disrupts the interaction between raptor and 
PRAS40 (183-185). 
 
Regulation of PRAS40-Thr246 phosphorylation. Thr246 of PRAS40 is embedded in a 
perfect and highly conserved consensus sequence for phosphorylation by PKB/Akt, i.e. 
Arg-x-Arg-xx-[pSer,pThr] (186) (Figure 1B). Indeed, incubation of PRAS40 with 
recombinant PKB/Akt promotes phosphorylation of Thr246 (187). Furthermore, activation 
of PKB/Akt alone is sufficient to induce Thr246 phosphorylation in NIH3T3 fibroblasts 
(188), whereas treatment of BT474 tumour cells with the PKB/Akt-inhibitor GSK690693 
lowers phosphorylation of Thr246 (189). The amino acid context of Thr246 also displays 
similarities with the optimal phosphorylation site for the oncogene-encoded protein kinase 
PIM1 (190), and very recently PIM1 has been shown to phosphorylate Thr246 in in vitro 
kinase assays and following enforced expression of PIM1 in murine myeloid FDCP1 cells 
(191).  
Studies in cultured cell lines show that Thr246 phosphorylation is promoted by insulin, 
NGF, and PDGF, and abrogated by the PI3K-inhibitors wortmannin and LY294002 (192-
194). Furthermore, PDGF-mediated Thr246 phosphorylation is almost completely 
abrogated in embryonic fibroblasts derived from mice lacking both Akt1 and Akt2 
(195;196).  
The regulation of PRAS40-Thr246 phosphorylation by PKB/Akt seems dependent on 
phosphorylation of Ser473 of PKB/Akt by the mTORC2-complex. Inhibition of mTORC2 
activity, either pharmacologically or by silencing of rictor, reduces Thr246-phosphorylation 
of PRAS40 (2;197). Finally, some studies show a partial inhibition of PRAS40-Thr246 
phosphorylation by rapamycin (198-200). Although mTORC2 has been reported to be 
insensitive to rapamycin, prolonged exposure to rapamycin has been shown to inhibit 
mTORC2 activity in certain eukaryotic cell types (201;202). Alternatively, efficient 
phosphorylation of Thr246 by the PI3K-PKB/Akt-mTORC2 pathway may require 




Phosphorylation of PRAS40 by mTORC1. The observation that the interaction of PRAS40 
with 14-3-3 proteins is completely dependent on the presence of amino acids, whereas the 
PKB/Akt-dependent phosphorylation of PRAS40 on Thr246 is only partially abrogated by 
amino acid deprivation, suggests that additional mTORC1-mediated phosphorylations are 
required for 14-3-3 binding to PRAS40 (205;206). Indeed, in vitro kinase assays on 
mTORC1 immunoprecipitates identified additional phosphorylation sites on Ser183, 
Ser202/Ser203, Ser212, and Ser221 in PRAS40 (207;208). In cultured cells, Ser183 is 
promoted by amino acids and insulin, and blunted by rapamycin, glucose withdrawal and 
amino acid starvation, thus providing further support that Ser183 is phosphorylated by 
mTORC1 (209;210). Although insulin was found to promote phosphorylation of 
Ser202/Ser203, Ser212, and Ser221 in HEK293 cells in vivo, only phosphorylation of 
Ser221 was sensitive to rapamycin (211). Therefore, the phosphorylation of Ser202/203 and 
Ser212 is probably mediated by as yet unknown protein kinases other than mTORC1.  
 
Binding of PRAS40 with 14-3-3 protein. The binding of 14-3-3 proteins to PRAS40 is 
prevented by inhibition of PI3K-activity and amino acid deprivation (212-214). 
Accordingly, substitution of Ser221 or Thr246 by Ala in PRAS40 almost completely 
abolished the insulin-induced binding of 14-3-3 proteins to PRAS40 (215;216). 
Interestingly, mutations of Phe129 in the TOS-motif, or Ser183 or Pro185 in the potential 
RAIP-motif all prevented 14-3-3 binding and reduced Thr246 phosphorylation (217;218). 
Thus, although the binding of 14-3-3 proteins is clearly dependent on both PKB/Akt- and 
mTORC1-mediated phosphorylation of PRAS40, the precise contribution of the mTORC1-
regulated sites requires further studies, such as analysis of Ser183 phosphorylation in 
PRAS40 mutants with a substitution of Ser221 or Thr246. 
It has been proposed that 14-3-3 binding is important for mTORC1 activation by 
sequestering PRAS40 away from mTORC1, and thereby relieving any inhibitory action that 
PRAS40 has on mTORC1. Indeed co-expression of 14-3-3 enhances the phosphorylation of 
S6K1 induced by a constitutively active mutant of PKB/Akt (219). However, the inhibition 
of mTORC1 in vitro kinase activity, or mTORC1 signalling by PRAS40, was independent 
of the presence of or the ability to interact with 14-3-3 proteins (220;221). It is currently 
unknown whether 14-3-3 binding may serve to alter the subcellular localization of 
PRAS40. Therefore, the physiological significance of 14-3-3 binding to PRAS40 remains 
as yet unclear.  
 
Cellular functions of PRAS40 
Regulation of mTORC1 activity and cell growth. In addition to being a substrate for 
mTORC1, multiple studies also identify PRAS40 as a negative regulator of mTORC1 
activity and cell growth. The presence of recombinant PRAS40 in in vitro kinase assays 
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inhibits both mTORC1 autophorylation and the induction of 4EBP1 and S6K1 
phosphorylation (2;222;223). Accordingly, overexpression of PRAS40 lowered basal 
phosphorylation S6K1 and 4EBP1 in multiple cell lines (224-227). These initial reports 
suggest that PRAS40 functions as substrate inhibitor of mTORC1, and that phosphorylation 
of PRAS40, which results in dissociation of PRAS40 from mTORC1, relieves the 
inhibitory constraint on mTORC1. Indeed, silencing of PRAS40 increased basal S6K1 
phosphorylation (228). A similar effect on S6K from Drosophila melanogaster was 
observed upon silencing of Lobe (229). Consistent with a role for PRAS40 as negative 
regulator of mTORC1, overexpression of PRAS40 led to a significant reduction in cell size 
(230;231). Reciprocally, silencing of Lobe in insect cells increased cell size (232). 
However, phorbol esters activate mTORC1 without affecting PRAS40 phosphorylation 
(233), leaving the possibility that the regulation of mTORC1 activity is stimulus-specific.  
The inhibitory effect of PRAS40 on mTORC1 activity seems to require the interaction with 
raptor, as a PRAS40 mutant with Phe129 replaced by Ala, which cannot bind raptor, does 
not affect 4EBP1 phosphorylation in vitro and S6K1 phosphorylation in vivo (234). Also 
overexpression of another raptor-binding mutant, Ser183Asp PRAS40, had no inhibitory 
effect on S6K1 phosphorylation (235). Based on these findings, it has been proposed that 
PRAS40 functions as an inhibitor of substrate binding on raptor. Silencing of PRAS40 was 
found to enhance 4EBP1 binding to raptor, whereas recombinant wild type, but not 
Phe129Ala-PRAS40, competed with 4EBP1 binding to raptor (236). In line with this, 
overexpression of either 4EBP1 or S6K1 lowered the binding of PRAS40 to raptor and 
reduced mTORC1-mediated phosphorylation of PRAS40 on Ser183 (237).  Another report, 
however, does not support a requirement for raptor-binding as the Phe129Ala PRAS40 
mutant inhibited insulin-mediated 4EBP1 phosphorylation to a similar extent as wild type 
PRAS40 (238). The reason for this discrepancy is as yet unclear. 
Strikingly, whereas silencing of PRAS40 has been found to enhance amino acid induced 
phosphorylation of 4EBP1 and S6K1 in one study (239), other reports show that both 
amino acid- and insulin-induced phosphorylation of 4EBP1 and S6K1 are reduced in the 
absence of PRAS40 (240-243). The requirement of PRAS40 for the phosphorylation of 
mTORC1 substrates, therefore, also suggests a role for PRAS40 in the assembly or 
integrity of the mTORC1 complex. Clearly, more studies are required to explain the 
discrepancies in literature and further detail the function of PRAS40 in the regulation of 
mTORC1. 
 
Apoptosis. PRAS40 has been linked to the regulation of cell survival and apoptosis. 
Overexpression of PRAS40 protects neurons from apoptotic cell death transient focal 
cerebral ischemia or spinal cord injury (244;245). It has been proposed that ischemia and 
reperfusion-mediated PRAS40-Thr246 phosphorylation and subsequent 14-3-3 binding 
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play a critical role in the protection of neuronal cells from apoptosis induced by ischemia in 
vivo (246;247).  Also Lobe has been implicated in the regulation of cell survival during eye 
development in Drosophila melanogaster (248). Conversely, lowering PRAS40 expression 
has been found to protect against the induction of apoptosis by tumour necrosis factor α or 
cyclohexamide (2). As rapamycin fails to mimic the pro-apoptotic effect of PRAS40 
silencing, it was suggested that PRAS40 may regulate apoptosis independent of mTORC1. 
The role of mTORC1 signaling has not been determined in the other studies on the role of 
PRAS40 in apoptosis. Given the observed differences of the impact of PRAS40 silencing 
on mTORC1 signaling (249-253), the role of mTORC1 in the regulation of apoptosis by 
PRAS40 therefore requires further studies. 
 
Deregulation of PRAS40 in disease 
Insulin resistance. The induction of PRAS40-Thr246 phosphorylation by insulin in vivo is 
reduced in skeletal muscle, heart, liver, and adipose tissue from insulin-resistant high-fat 
diet fed rats, and skeletal muscle from ob/ob mice (254-256). Also incubation of rat soleus 
muscle with palmitate lowers the induction of PRAS40-Thr246 phosphorylation by insulin 
(257). Improving insulin sensitivity by weight loss improved the induction of PRAS40-
Thr246 in human skeletal muscle response to hyperinsulinemia (258).  
It is unclear whether the reduction in insulin-mediated PRAS40-Thr246 phosphorylation 
affects the activity of mTORC1, or results from hyperactivation of the mTORC1 pathway. 
It has been proposed that the increase in basal S6K1 phosphorylation caused by silencing of 
PRAS40 induces degradation of IRS1, which on its turn reduces insulin-induced 
phosphorylation of PKB/Akt (259). However, other studies could not demonstrate an affect 
of either silencing or overexpression of PRAS40 on PKB/Akt phosphorylation (260;261). 
Also acute treatment of ob/ob mice with rapamycin did not improve insulin sensitivity in 
ob/ob mice despite elevated activity of mTORC1 in skeletal muscle (262). A limitation of 
this study, however, is that the phosphorylation of IRS1, PKB/Akt and PRAS40 was not 
assessed after rapamycin treatment. Therefore, further studies, including the effects of 
alterations in insulin sensitivity on the other PRAS40 phosphorylation sites, are required to 
determine the physiological consequences of a reduced PRAS40-Thr246 phosphorylation in 
insulin resistance. 
 
Cancer. Both the expression and Thr246-phosphorylation of PRAS40 are elevated in pre-
malignant and malignant breast and lung cancer cell lines (263). Furthermore, levels of 
Thr246-phosphorylated PRAS40 were increased in meningiomas, and malignant 
melanomas (264;265). The increase in PRAS40 phosphorylation in during melanoma 
tumour progression was paralleled by increased Akt3 activity (266). However, also other 
oncogenic protein kinases, like PIM1 (267), may contribute to enhanced PRAS40-Thr246 
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phosphorylation as PRAS40-Thr246 phosphorylation in tumour was only lowered by 
incubation with wortmannin (268). Interestingly, lowering PRAS40-Thr246 
phosphorylation associates with an increased sensitivity of tumour cells to pro-apoptotic 
stimuli (269), suggesting the PRAS40 plays a critical role in tumour cell survival. 
 
Conclusions and perspectives 
The identification of PRAS40 as regulator and substrate of both mTORC1 and PKB/Akt 
has added to the complexity of mTORC1 signalling. Future challenges lie in further 
detailing the impact of the alterations in PRAS40 phosphorylation, as observed in insulin 
resistance and cancer, on mTORC1-activity and insulin signalling through the IRS1-
PKB/Akt pathway. Furthermore, it would be interesting whether PRAS40 also affects the 
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Clinical insulin resistance is associated with decreased activation of phosphatidylinositol 
3’-kinase (PI3K) and its downstream substrate protein kinase B (PKB)/Akt. However, its 
physiological protein substrates remain poorly characterized. In the present study, the effect 
of in vivo insulin action on phosphorylation of the PKB/Akt substrate 40 (PRAS40) was 
examined. In rat and mice, insulin stimulated PRAS40-Thr246 phosphorylation in skeletal 
and cardiac muscle, the liver, and adipose tissue in vivo. Physiological hyperinsulinemia 
increased PRAS40-Thr246 phosphorylation in human skeletal muscle biopsies. In cultured 
cell lines, insulin-mediated PRAS40 phosphorylation was prevented by the PI3K inhibitors 
wortmannin and LY294002. Immunohistochemical and immunofluorescence studies 
showed that phosphorylated PRAS40 is predominantly localized to the nucleus. Finally, in 
rats fed a high-fat diet (HFD), phosphorylation of PRAS40 was markedly reduced 
compared with low-fat diet-fed animals in all tissues examined. In conclusion, the current 
study identifies PRAS40 as a physiological target of in vivo insulin action. Phosphorylation 
of PRAS40 is increased by insulin in human, rat, and mouse insulin target tissues. In rats, 
this response is reduced under conditions of HFD-induced insulin resistance. 
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Introduction 
Insulin resistance and type 2 diabetes are associated with impaired insulin action in 
peripheral tissues like skeletal muscle, adipose tissue, liver, and the heart (1). Insulin action 
is initiated by binding of insulin to its receptor, leading to activation and phosphorylation of 
the receptor tyrosine kinase, which in turn phosphorylates several endogenous substrates, 
including the insulin receptor substrate proteins (1). Tyrosine phosphorylation of the insulin 
receptor substrate proteins facilitates the binding and activation of phosphatidylinositol 3’-
kinase (PI3K), thus catalyzing the formation of phosphatidylinositol 3,4,5-trisphosphate 
and providing a platform for the binding and activation of protein kinase B (PKB)/Akt (1). 
Numerous studies have linked PKB/Akt to the regulation of glucose metabolism, cell 
growth, and antiapoptosis (2,3). However, the endogenous substrates regulating these 
responses are only starting to become characterized (4). 
The PKB/Akt protein kinase phosphorylates proteins on serine (S/Ser) or threonine (T/Thr) 
residues within a RxRxxpS/pT motif (5). The use of phospho-specific antibodies 
recognizing this PKB/Akt consensus sequence led to the identification of multiple novel 
proteins, including proline-rich Akt substrate 40 (PRAS40; also known as Akt1 substrate 1 
[Akt1S1]) (6,7). PRAS40 is ubiquitously expressed and appears to be localized to the 
nucleus (7,8). In response to growth factors, PRAS40 is phosphorylated on Thr246 via 
PI3K- and PKB/Akt-dependent signaling pathways (6,8). In vitro, phosphorylation of 
PRAS40 facilitates the binding of 14-3-3 proteins, and this protein complex has been 
implicated in nerve growth factor–mediated neuroprotection from ischemia (8). Although 
PRAS40 is phosphorylated in response to stimulation of cultured cells with insulin in vitro 
(6,9), it is as yet unknown whether this protein is involved in physiological insulin action. 
In the present study, we analyzed whether PRAS40-Thr246 phosphorylation is induced in 
response to in vivo insulin treatment in various insulin target tissues in humans, rats, and 
mice. Furthermore, we studied whether this response is altered under conditions of high-fat 
diet (HFD)-induced insulin resistance. 
 
Materials and methods 
Materials and cell lines. A14 cells are NIH3T3 fibroblasts overexpressing the human 
insulin receptor (10). H9c2-E2 cells are cardiomyocytes overexpressing the human insulin 
receptor (11). Wortmannin, LY294002 and rapamycin were purchased from Calbiochem 
(Darmstadt, Germany). U0126 was obtained from Promega (Benelux, Leiden, the 
Netherlands). Anti–phospho (Ser/Thr)-Akt-substrate (#9611), anti–phospho-Ser473-
PKB/Akt (#9271, #4051), anti–phospho-Thr421/Ser424-p70 S6 kinase (#9204), anti–
phospho-Thr202/Tyr204–extracellular signal–related kinase (ERK) 1/2 (# 9101), and anti–
phospho-glycogen synthase kinase (GSK) 3 α/ß-Ser21/Ser9 (#9331) were from Cell 
Signaling Technology (Beverly, MA); anti–phospho-PRAS40-Thr246 (44–100G) and anti–
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phospho-AS160-Thr642 (44–1071G) were from Biosource International (Camarillo, CA); 
and anti-AS160 (ab5909) was from Abcam (Cambridge, U.K.). PKB/Akt antiserum was 
kindly provided by Dr. B. Burgering (Utrecht University, Utrecht, the Netherlands). 
PRAS40 antibody was kindly provided by Dr. R. Roth (Stanford University, Stanford, CA) 
(6). 
Human biopsies. Muscle biopsies were obtained from 10 obese subjects with type 2 
diabetes (8 female and 2 male subjects, aged 54 ± 3 years, with fasting plasma glucose 11.1 
± 0.8 mmol/l, HbA1c 7.7 ± 0.4%, and BMI 40.2 ± 1.6 kg/m2) participating in a clinical 
study that was approved by the medical ethical committee of the Leiden University Medical 
Center. Patients used at least 30 units of exogenous insulin; eight patients also used 
metformin, and two patients used rosiglitazone. Written informed consent was obtained 
from the patients following explanation of the experimental procedures. Biopsies were 
collected following an overnight fast (baseline) and 30 min after initiation of a 
hyperinsulinemic-euglycemic clamp (insulin infusion rate: 40 mU/m2 per min) (12,13). 
Muscle biopsies were taken from the vastus lateralis muscle after localized anesthesia with 
1% lidocaine with a modified Bergström needle and snap frozen in dry ice–chilled 
isopentane (14). 
Animals. The investigation conformed to the Guide for the Care and Use of Laboratory 
Animals, as published by the National Institutes of Health (NIH publ. no. 85-23, revised 
1996) and the regulations of the institutional animal care and use committee. Adult male 
Wistar WU rats (n = 20; mean body weight 302 ± 6 g) were obtained form Harlan CBP 
(Horst, the Netherlands). Animals were fed an HFD or a low-fat diet (LFD) for 7 weeks as 
described (15). Rats were fasted for 6 h, and insulin stimulation was induced through 
intraperitoneal injection of 10 units/kg body wt insulin (Actrapid 100 units/ml; Novo 
Nordisk, Alphen Aan Den Rÿn, the Netherlands) 30 min before being killed by 
decapitation. Animals were considered insulin stimulated when the plasma insulin levels 
exceeded 2 nmol/l. Similar insulin levels were achieved in HFD- and LFD-fed rats (data not 
shown). Control animals received an intraperitoneal injection with saline. Trunk blood was 
collected for glucose determinations using a HemoCue glucose analyzer (Angelholm, 
Sweden). Plasma insulin levels were determined as described (15). Male C57BL6/J mice (n 
= 12; mean body weight 23.2 ± 2 g), obtained from Charles River (Maastricht, the 
Netherlands), were fasted overnight and anesthetized by intraperitoneal injection with a 
combination of 6.25 mg/kg acetylpromazine (Sanofi Santé Nutrition Animale, Libourne 
Cedex, France), 6.25 mg/kg midazolam (Roche, Mijdrecht, the Netherlands), and 0.3125 
mg/kg fentanyl (Janssen-Cilag, Tilburg, the Netherlands). Insulin was infused at 24.5 pmol 
· kg body wt–1 · min–1 as described (16). Glucose was coinfused with insulin at 105 
µmol/min to maintain euglycemia (4.7 ± 0.7 mmol/l). Blood glucose was measured with the 
FreeStyle hand glucose measurer (Therasense; Disetronic Medical Systems, Vianen, the 
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Netherlands). At 10, 15, and 20 min following initiation of the insulin infusion, mice were 
killed by cervical dislocation. Control animals were killed following a 20-min infusion with 
PBS. Organs were removed and either immersion fixed in 4% buffered formaldehyde 
solution or snap frozen in dry ice–chilled isopentane and stored at –80°C until further use. 
Western blotting. Homogenates of tissue biopsies were prepared in 30 mmol/l Tris.HCl, pH 
7.5, 150 mmol/l NaCl, 0.5% Triton X100, 0.5% sodium deoxycholate, 1% SDS, 1 mmol/l 
Na3VO4, 10 mmol/l NaF, and Complete protease inhibitors (Roche). Cultured cells were 
lysed in 100 mmol/l Tris.HCl, pH 6.8, 3% SDS, and 10% glycerol. Homogenates were 
cleared by centrifugation (13.200 rpm; 15 min, 4°C). Protein content was determined using 
a bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Expression and 
phosphorylation of proteins was determined by SDS-PAGE and immunoblotting (15). 
Bound antibodies were visualized by enhanced chemiluminescence and quantified by 
densitometry analysis of scanned films (ImageJ 1.34S; National Institutes of Health, 
Bethesda, MD). 
Immunohistochemistry. Fixed tissues were prepared by routine paraffin embedding 
(Histowax). Sections (6 µm) were cut and mounted on 3-aminopropyltriethoxisilane–coated 
slides (Menzal, Darmstadt, Germany) to prevent detachment due to the high temperature 
during antigen retrieval treatment, which was necessary for the visualization of phospho-
PRAS40-Thr246 antibody. After deparaffinization and rehydration, the slides were heated 
(12 min at 900 W) in 0.01 mol/l citrate buffer (pH 6.0). The sections were allowed to cool 
down at room temperature, were rinsed extensively with Tris-buffered saline (TBS; 50 
mmol/l Tris.HCl and 500 mmol/l NaCl, pH 7.6), and were incubated overnight with the 
phospho-PRAS40-Thr246 antibody diluted (1:1000) in TBS containing 0.5% Triton X100, 
pH 7.6, at 4°C. After several washes in TBS, sections were incubated with biotinylated 
anti-rabbit IgG (1.5 h at room temperature; Vector Laboratories, Burlingame, CA) and 
diluted (1:250) in TBS, followed by avidin-biotin-peroxidase (1 hr, RT, 1:400, ABC Elite 
kit; Vector Laboratories). Tissue-bound peroxidase was visualized with the 3,3'-
diaminobenzidine tetrahydrochloride chromogen reaction (7.5 mg diaminobenzidine 
tetrahydrochloride, 5 µl 30% H2O2 in 15 ml 50 mmol/l Tris.Cl, pH 7.6) for 10 min at RT. 
Sections were then rinsed with distilled water, dehydrated in a graded series of ethanol, 
cleared in xylene, and coverslipped with Entellan (Merck, Darmstadt, Germany). 
Immunofluorescence. Cells grown on coverslips (18 mm) were rinsed with ice-cold PBS 
and fixed in 3.7% formaldehyde in TBS (25 mmol/l Tris.HCl, 100 mmol/l NaCl, 5 mmol/l 
KCl, 0.7 mmol/l CaCl2, and 0.5 mmol/l MgCl2, pH 7.4) (15 min at room temperature). To 
quench residual cross-linking, coverslips were rinsed with 50 mmol/l NH4Cl in TBS (10 
min at room temperature) and subsequently permeabilized with 0.1% Triton X-100 in TBS 
(5 min at room temperature). Cells were washed with 0.2% BSA/TBS, blocked with 0.2% 
BSA/TBS (30 min at room temperature), and incubated with primary antibodies diluted 
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(1:100) in 0.2% BSA/TBS (overnight, 4°C). After 0.2% BSA/TBS washes, coverslips were 
incubated with appropriate secondary antibodies diluted (1:100) in 0.2% BSA/TBS (2 h at 
room temperature). Subsequently, coverslips were cleaned with 0.2% BSA/TBS and TBS 
and milliQ and mounted in 4’,6-diamidino-2-phenylindole [DAPI]-containing Vectashield 
solution (Vector Laboratories). Fluorescence was detected using a Leica DM-RXA 
microscope (filters DAPI, fluorescein isothiocynate, and TRITC [tetramethylrhodamine 
isothiocyanate]). 
Data analysis. Data are expressed as mean ± SEM. Differences between groups were 
determined by unpaired Student’s two-tailed t test, using Macintosh version 11.0.4 (SPSS, 
Chicago, IL). p < 0.05 was considered statistically significant. 
 
Results  
Characterization of endogenous PKB/Akt substrates in insulin target tissues. The effects 
of in vivo insulin stimulation on the phosphorylation of endogenous PKB/Akt substrates in 
rat liver, adipose tissue, and cardiac and skeletal muscle were assessed by immunoblotting 
with the phospho (Ser/Thr)-PKB/Akt-substrate antibody. In all examined tissues, insulin 
induced the phosphorylation of a ~30 kDa (p30) and a ~40 kDa (p40) protein (Fig. 1A). 
Only in cardiac and skeletal muscle was phosphorylation of a ~160 kDa (p160) protein 
observed. Reprobing the stripped membranes with appropriate antibodies identified p30 as 
phosphorylated ribosomal protein S6. This was subsequently confirmed by cell 
fractionation and isolating the ribosomal 40S and 60S subunits by sucrose gradient 
fractionation (data not shown). The p160 protein was identified as Akt substrate 160 
(AS160) (data not shown). p40 migrated at a molecular weight similar to GSK3β and 
PRAS40 (data not shown). Isoelectric focusing of liver homogenates followed by SDS-
PAGE and immunoblotting showed that a 40 kDa PKB/Akt substrate immunoreactivity 
was predominantly found at the acidic region at an isoelectric point corresponding to 
PRAS40 (calculated isoelectric point 4.7) rather than GSK3ß (calculated isoelectric point 
9.0) (Fig. 1B). Reprobing the stripped filter with the phospho–PRAS40-Thr246 antibody 
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Figure 1. A. Phosphoproteins detected by the PKB/Akt substrate 
antibody in rat liver, skeletal muscle, cardiac ventricular tissue, and 
adipose tissue following intraperitoneal saline (-) or insulin (+) 
injection. B. Identification of p40 as PRAS40. Immunoblots prepared 
after isoelectric focusing of liver homogenate from insulin-treated 
rats were incubated with the PKB/Akt substrate antibody and the 
PRAS40 antibody, respectively 
 
Insulin induces PRAS40-Thr246 phosphorylation. Whereas ribosomal protein S6 and 
AS160 have been implicated in the regulation of protein synthesis and glucose transport, 
respectively, little is known on the function of PRAS40 in insulin action. Therefore, we 
decided to focus on regulation of this protein. Figure 2A shows that PRAS40-Thr246 
phosphorylation was induced in mouse liver and skeletal and cardiac muscle within 10 min 
after initiation of an insulin infusion (24.5 pmol · kg body wt–1 · min–1). The onset of 
PRAS40-Thr246 phosphorylation in these murine tissues correlated with the induction of 
PKB/Akt-Ser473 phosphorylation, whereas protein expression levels of PRAS40 and 
PKB/Akt were similar at the various time points examined (Fig. 2A). In rats, intraperitoneal 
injection of insulin (30 min, 10 units/kg body wt) stimulated PRAS40-Thr246 
phosphorylation in the liver, heart, skeletal muscle, and adipose tissue (Fig. 2B). Protein 
expression of PRAS40 was similar between saline and insulin-injected samples. Also, in 
skeletal muscle biopsies obtained from obese subjects with type 2 diabetes, a 2.5 ± 0.4–fold 
increase (n = 8; p < 0.02) in PRAS40-Thr246 phosphorylation was found 30 min after 
initiation of the hyperinsulinemic-euglycemic clamp at an insulin infusion rate of 40 
mU/m2 per min (Fig. 2C). The increase in PRAS40-Thr246 phosphorylation in response to 
hyperinsulinemia was paralleled by a 1.9 ± 0.3–fold increase in AS160-Thr642 
phosphorylation (n = 8; p < 0.01) and could not be ascribed to differences in PRAS40 and 





Figure 2. A. Phosphorylation and protein expression of PRAS40 and PKB/Akt in mouse liver, skeletal muscle, and 
heart following in vivo insulin infusion during 10, 15, and 20 min. Control animals received PBS (0). B. 
Phosphorylation and protein expression of PRAS40 in rat liver, skeletal and cardiac muscle, and adipose tissue 
following intraperitoneal saline (-) or insulin (+) injection. C. Phosphorylation and protein expression of PRAS40 
and AS160 in human skeletal muscle biopsies under basal and hyperinsulinemic-euglycemic conditions. All 
experiments are representative of at least three independent observations 
 
Studies in cultured rat H9c2-E2 cardiomyocytes showed a 2.6 ± 0.1–fold induction of 
PRAS40-Thr246 phosphorylation within 1 min and maximal stimulation (3.9 ± 0.3–fold 
over basal) within 2 min after the addition of insulin (Fig. 3). Also, in A14 fibroblasts and 
3T3L1 adipocytes (data not shown), induction of PRAS40-Thr246 phosphorylation was 
observed within 1 min after the addition of insulin. The presence of the PI3K inhibitors 
wortmannin or LY294002 (data not shown) abrogated the phosphorylation of PRAS40 and 
PKB/Akt in response to insulin stimulation (Fig. 3A). Inhibition of the mammalian target of 
rapamycin (mTOR)/p70 S6 kinase and mitogen-activated protein kinase kinase 
(MEK)/ERK1/2 pathways by rapamycin and U0126, respectively, had no effect on 
phosphorylation of PKB/Akt or PRAS40 after insulin stimulation (Fig. 3B), indicating that 
PRAS40 is a distal component of the class I PI3K/PKB/Akt-mediated signaling pathway 
rather than the class III PI3K/mTOR pathway. 




Figure 3. Effect of wortmannin (A) and U0126 and rapamycin (B) on the phosphorylation of PRAS40-Thr246 
following stimulation of H9c2-E2 cardiomyocytes with 100 nmol/l insulin. Comparable exposures for PRAS40-
Thr246 blots are shown. When indicated, cells were pretreated with wortmannin (100 nmol/l, 30 min), U0126 (10 
µmol/l, 15 min), or rapamycin (100 nmol/l, 15 min). Effectiveness of wortmannin, U0126, and rapamycin was 
verified by reprobing the membranes with phospho-specific antibodies for PKB/Akt, ERK1/2, and p70 S6 kinase, 
respectively. Equal loading was verified by reprobing the blots with PKB/Akt antibody. 
 
Phosphorylated PRAS40 is localized in the nucleus. Immunohistochemical staining of 
liver and cardiac ventricular tissue from insulin-injected rats with the phospho-PRAS40-
Thr246 antibody shows a nuclear localization of the protein both in hepatocytes and 
cardiomyocytes (Fig. 4). Immunofluorescence labeling of A14 and H9c2-E2 cells with 
phospho–PRAS40-Thr246 antibodies substantiated the predominant nuclear localization of 
PRAS40. In response to insulin stimulation, the nuclear phospho–PRAS40-Thr246 
immunoreactivity was markedly increased. Some PRAS40 staining was observed in the 
cytoplasm in the vicinity of phosphorylated PKB/Akt (Fig. 5B). The insulin-mediated 
increase in phospho–PRAS40-Thr246 immunoreactivity was prevented in the presence of 
LY294002 (Fig. 5). 
 
 
Figure 4. Immunohistochemical staining of rat liver and cardiac ventricular tissue sections with PRAS40-Thr246 
antibody. Rats received an intraperitoneal injection with insulin 30 min before they were killed. Photographs are 




Figure 5. Immunofluorescence staining of H9c2-E2 cardiomyocytes (A) and A14 fibroblasts (B). Cells were 
stimulated with 100 nmol/l insulin and where indicated pretreated with LY294002 (25 µmol/l, 15 min). Cells were 
fixed and stained with phospho-specific PRAS40-Thr246 antibody followed by fluorescein isothiocyanate–
conjugated anti-rabbit IgG (green) or phospho-specific PKB-Ser473 antibody followed by tetramethylrhodamine 
isothiocyanate (TRITC)-conjugated anti-mouse IgG (red). DNA was stained with DAPI (blue). Photographs are 
representative of three independent experiments 
 
Impaired insulin-mediated phosphorylation in tissues from HFD-fed rats. We next 
examined whether the induction of PRAS40-Thr246 phosphorylation by insulin was altered 
under conditions of HFD-induced insulin resistance in rats. Tissues were collected from the 
same rats already described in a previous study, where we showed that HFD induced 
impaired glucose tolerance, myocardial insulin resistance, and skeletal muscle and hepatic 
steatosis (15). Following a 7-week exposure to a HFD, fasting blood glucose values were 
increased compared with rats fed an isocaloric LFD (p < 0.005; Table 1). No changes in 
body weight and fasting plasma insulin levels were observed between LFD- and HFD-fed 
rats (Table 1). In skeletal muscle, insulin versus saline stimulated PRAS40-Thr246 
phosphorylation by 19.6-fold in LFD-fed rats and 9.0-fold in HFD-fed rats (p < 0.05), 
respectively (Fig. 6A; Table 2). Also, PKB/Akt Ser473 phosphorylation and AS160-Thr642 
phosphorylation were increased in skeletal muscle from insulin-injected LFD-fed rats but 
not in muscles from HFD-fed animals (Fig. 6A). Protein expression of PRAS40 and 
PKB/Akt did not differ among the experimental groups (Fig. 6A). In the heart, insulin 
stimulated PRAS40-Thr246 phosphorylation by 6.7-fold in LFD- fed rats and 2.2-fold in 
HFD-fed rats (p < 0.05) (Fig. 6B; Table 2). In the liver, a 2.5-fold increase in PRAS40-
Thr246 phosphorylation was observed in LFD-fed animals, and this response was 
completely abrogated in livers from HFD-fed rats (p < 0.05) (Fig. 6C; Table 2). In adipose 
tissue, insulin stimulated PRAS40-Thr246 phosphorylation by 4-fold in LFD-fed rats and 
by 1.5-fold in HFD-fed rats (p < 0.05) (Fig. 6D; Table 2). Rats exposed to the same HFD 
for a period of 10–20 weeks also showed insulin resistance for the induction of PRAS40-
Thr246 phosphorylation (data not shown). 
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Table 1. Animal characteristics following a 7-week LFD- or HFD-intervention 
 Low-fat diet (n=10) High-fat diet (n=10) 
Body weight at sacrifice (gram) 446.4 ± 20.9 454.7 ± 21.2 
Fasting blood glucose (mmol/L) 6.02 ± 0.60     6.97 ± 0.60* 
Fasting plasma insulin (mU/L) 56.7 ± 15.6 51.5 ± 6.9 
Values are mean ± SD 
*p < 0.05 versus LFD 
 
 
Figure 6. Phosphorylation and protein expression of PRAS40, PKB/Akt, AS160, and GSK3α/ß in skeletal muscle 
(A), cardiac ventricular tissue (B), liver (C), and adipose tissue (D) from LFD- and HFD-fed rats. Thirty minutes 
before they were killed, rats received an intraperitoneal injection with saline or insulin (10 units/kg body wt). The 
immunoblots shown are representative of observations on at least four animals per experimental group 
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In all tissues, the insulin-mediated changes in PRAS40-Thr246 phosphorylation and the 
blunted response in tissues from HFD-fed rats were paralleled by comparable changes in 
PKB/Akt Ser473 phosphorylation. Only in skeletal muscle could we reproducibly detect 
insulin-induced AS160-Thr642 phosphorylation. Therefore, we analyzed the other tissues 
for insulin-mediated phosphorylation of another PKB/Akt substrate (i.e., GSK3). In heart 
and liver, the induction of GSK3 α/ß-Ser21/9 phosphorylation in response to insulin closely 
resembled the induction of PKB/Akt and PRAS40 phosphorylation (Fig. 6B and C). In 
adipose tissue, basal phosphorylation of GSK3 α/ß was elevated in adipose tissue from 
HFD-fed rats, and while insulin stimulated GSK3 α/ß-Ser21/9 phosphorylation in LFD-fed 
adipose tissue, this stimulatory effect was absent in adipose tissue from HFD rats (Fig. 6D). 
Collectively, these observations agree with a situation in which the phosphorylation state of 
PRAS40 is predominantly regulated through insulin-mediated activation of PKB/Akt. 
 
Discussion 
The serine/threonine kinase PKB/Akt has been identified as a crucial mediator of insulin 
action. Activation of this kinase contributes, among others, to the regulation of glucose 
uptake, glycogen metabolism, gene expression, cell survival, and proliferation and 
protection from apoptosis (3,17). The use of phospho-specific antibodies recognizing the 
PKB/Akt consensus phosphorylation site RxRxx(pS/pT) has led to the identification of 
several novel putative substrates for PKB/Akt (4), including AS160 (18), ATP-citrate lyase 
(19), PIKfyve (20), Wnk1 (21), and PRAS40 (6,7), in addition to already known substrates 
like the forkhead/FOXO transcription factors, endothelial nitric oxide synthase, mTOR, 
GSK3, and Bad (2). However, when analyzing target tissues for insulin action, among the 
most prominent proteins that are recognized by the PKB/Akt-substrate antibody was p40, 
which was identified as PRAS40. In the present study, we demonstrate that phosphorylation 
of PRAS40 is induced in response to in vivo insulin stimulation in various target tissues 
and that phosphorylation of this protein is markedly blunted under conditions of HFD-
induced insulin resistance. 
PRAS40 is ubiquitously expressed in all tissues examined thus far but was originally 
characterized in rat H4IIE hepatoma cells, 3T3L1 adipocytes, and HeLa cell nuclear 
extracts using the PKB/Akt substrate antibody (6,7,9). Interestingly, phosphorylation of an 
as yet unidentified ~46-kDa protein recognized by the PKB/Akt substrate antibody has 
been reported in insulin-stimulated human skeletal muscle, and phosphorylation of this 
protein is impaired in patients with type 2 diabetes. Given the induction of PRAS40-Thr246 
phosphorylation by insulin in human skeletal muscle observed here, it seems plausible that 
the 46-kDa protein is similar to PRAS40 (22). In the present study, a matched healthy 
control group was not available. However, improvement of insulin sensitivity induced by 
weight loss was accompanied by increased phosphorylation of PRAS40 (from 2.5- to 3.8-
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fold stimulation [p < 0.02] in response to 30 min hyperinsulinemia) (I.M.J., unpublished 
data), indicating that PRAS40-Thr246 phosphorylation is a bona fide marker for insulin 
sensitivity in human skeletal muscle. 
Phosphorylation of PRAS40 was also observed in response to other growth factors, 
including platelet-derived growth factor, epidermal growth factor, and nerve growth factor 
(6,8,23), and this process was completely abrogated in mouse embryonic fibroblasts lacking 
Akt1 and Akt2 (6). Inhibitors of PI3K, but not rapamycin and MEK1/2 inhibition, 
prevented the induction of PRAS40 phosphorylation by insulin. In various mice tissues 
examined (skeletal muscle, heart, and liver), the onset of PRAS40 phosphorylation 
following intravenous insulin infusion closely correlated with the onset of PKB/Akt 
phosphorylation (data not shown). Furthermore, in tissues from HFD-fed rats, the reduction 
in PRAS40 phosphorylation was accompanied by reduced phosphorylation of PKB/Akt and 
its substrates AS160 and GSK3α/ß. Collectively, these findings further identify PRAS40 as 
substrate for PKB/Akt also under physiological in vivo conditions. 
Notably, we only observed reproducible insulin-mediated phosphorylation of AS160 in 
skeletal muscle. Analysis of various insulin target tissues with the PKB/Akt-substrate 
antibody suggests that p160 phosphorylation is more prominent in skeletal muscle 
compared with other tissues. However, pilot studies indicate that insulin is capable of 
increasing phosphorylation of AS160-Thr642 in isolated rat cardiomyocytes (E.B.M.N., 
D.M.O., unpublished data), suggesting that the failure to detect a significant increase in 
AS160-Thr642 phosphorylation in hearts from insulin-injected rats may be related to the 
sensitivity of the antibody. 
Little is known about the function of the PRAS40 protein. Like others (7,8), we found that 
phosphorylated PRAS40 predominantly localizes to the nucleus, although in response to 
insulin stimulation phosphorylated PRAS40 also was found to localize in the vicinity of 
phosphorylated PKB/Akt in the cytoplasm. Furthermore, phosphorylated PRAS40 has been 
found to interact with 14-3-3 proteins (6,8,23). In line with a role of both 14-3-3 proteins 
and PKB/Akt in the regulation of cell survival (17,24), PRAS40 also has been implicated in 
this process, in particular in the protection of neurons against apoptosis following cerebral 
ischemia (8,25). Notably, PRAS40 phosphorylation in response to insulin was also 
observed in the arcuate nucleus of rats (data not shown). Whether PRAS40 also has 
antiapoptotic activity in skeletal and cardiac muscle, liver, and adipose tissue or whether it 
mediates another action of insulin remains to be demonstrated. 
In conclusion, the current study identifies PRAS40 as a novel physiological target of in 
vivo insulin action and a potential marker for insulin resistance. Phosphorylation of 
PRAS40 is increased by insulin in rat, mouse, and human insulin target tissues, and this 
response is reduced under conditions of HFD-induced insulin resistance. Although PRAS40 
has been implicated in the protection against neuronal apoptosis after stroke, its role in 
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insulin action is still unknown. Overexpression and knock down of PRAS40, as well as 
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Type 2 diabetes is associated with alterations in protein kinase B (PKB/Akt) and 
mammalian target of rapamycin complex 1 (mTORC1) signalling. The proline-rich Akt 
substrate of 40 kDa (PRAS40) is a component of mTORC1, which has a regulatory 
function at the intersection of the PKB/Akt- and mTORC1 signalling pathway. 
Phosphorylation of PRAS40-Thr246 by PKB/Akt, and PRAS40-Ser183 and PRAS40-
Ser221 by mTORC1 results in dissociation from mTORC1, and its binding to 14-3-3 
proteins. Although all phosphorylation sites within PRAS40 have been implicated in 14-3-3 
binding, substitution of Thr246 by Ala alone is sufficient to abolish 14-3-3 binding under 
conditions of intact mTORC1 signalling. This suggests that phosphorylation of PRAS40-
Thr246 may facilitate efficient phosphorylation of PRAS40 on its mTORC1-dependent 
sites. In the present study, we investigated the mechanism of PRAS40-Ser183 
phosphorylation in response to insulin. Insulin promoted PRAS40-Ser183 phosphorylation 
after a hyperinsulinaemic-euglycaemic clamp in human skeletal muscle. The insulin-
induced PRAS40-Ser183 phosphorylation was further evidenced in vivo in rat skeletal and 
cardiac muscle, and in vitro in A14 fibroblasts, 3T3L1 adipocytes and L6 myotubes. 
Inhibition of mTORC1 by rapamycin or amino acid deprivation partially abrogated insulin-
mediated PRAS40-Ser183 phosphorylation in cultured cell lines. However, lowering 
insulin-induced PRAS40-Thr246 phosphorylation using wortmannin or palmitate in cell 
lines, or by feeding rats a high-fat diet, completely abolished insulin-mediated PRAS40-
Ser183 phosphorylation. In addition, replacement of Thr246 by Ala reduced insulin-
mediated PRAS40-Ser183 phosphorylation. We conclude that PRAS40-Ser183 is a 
component of insulin action, and that efficient phosphorylation of PRAS40-Ser183 by 




The mammalian target of rapamycin complex 1 (mTORC1) regulates many cellular 
responses including protein synthesis, autophagy, mitochondrial function, and cell cycle 
progression (1-3). Activation of mTORC1 occurs through the amino acid-dependent 
binding of the GTP-bound form of the small GTP-binding protein Ras homolog-enriched in 
brain (Rheb) to its catalytic subunit, the mammalian target of rapamycin (mTOR) (4). The 
levels of GTP-bound Rheb are regulated by tuberous sclerosis complex (TSC), which acts 
as a GTPase activating protein on Rheb (5). Insulin inhibits the activity of TSC through 
phosphorylation of TSC2 by protein kinase B (PKB/Akt) (6;7). This relieves Rheb from the 
inhibitory GTPase activity and allows Rheb-GTP to activate mTORC1 (8).  
PKB/Akt also phosphorylates a component of mTORC1, the proline-rich Akt substrate of 
40-kDa (PRAS40) (9). Binding of PRAS40 to mTORC1 requires the TOR signalling motif 
located between Phe129 and Ile133, and may in addition involve the region between 
Lys182 and Pro185 (10-12). Incubation of cells with insulin, platelet-derived growth factor, 
nerve growth factor, or nutrients like glucose and amino acids induces the phosphorylation 
of PRAS40 on multiple residues, including Ser183, Ser221, and Thr246 (13-17). Whereas 
PKB/Akt has been identified as the main regulator of Thr246 phosphorylation (18), 
mTORC1 itself has been implicated in the phosphorylation of PRAS40 on Ser183, and 
Ser221 (19;20). Phosphorylation of PRAS40 disrupts the interaction between mTORC1 and 
PRAS40, which may relieve an inhibitory constraint on mTORC1 activity (21;22). 
Phosphorylated PRAS40 also binds to 14-3-3 chaperone proteins (23-25). The interaction 
between 14-3-3 proteins and PRAS40 requires both the PKB/Akt- and mTORC1-mediated 
phosphorylation of PRAS40 since inhibition of phosphatidylinositol 3’-kinase (PI3K) 
activity or amino acid deprivation almost completely abolishes insulin-induced binding of 
PRAS40 to 14-3-3 proteins (26-28). 
Insulin resistance is characterized by an impaired insulin-mediated activation of PI3K and 
PKB/Akt (29;30). Accordingly, alterations in insulin sensitivity were found to affect the 
PKB/Akt-regulated phosphorylation of PRAS40-Thr246 in vivo (31;32). Specifically, 
insulin-mediated PRAS40-Thr246 phosphorylation is reduced in tissues from insulin-
resistant high-fat diet fed rats and ob/ob-mice (33;34). Reciprocally, weight loss, which 
improves insulin sensitivity in obese insulin resistant patients, restores the induction of 
PRAS40-Thr246 phosphorylation in response to hyperinsulinaemia in skeletal muscle (35).  
It is unclear whether alterations in PRAS40-Thr246 phosphorylation impact on the activity 
of mTORC1. However, substitution of Thr246 by Ala is sufficient to abolish its binding to 
14-3-3 proteins under conditions of intact mTORC1 signalling (36;37). This raises the 
possibility that phosphorylation of PRAS40-Thr246 may facilitate efficient phosphorylation 
of PRAS40 on its mTORC1-dependent sites. In the present study, we therefore examined 
the regulation of PRAS40-Ser183 phosphorylation by insulin in both the physiological 
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situation, and under conditions of reduced Thr246-phosphorylation, by either 
pharmacological inhibition of PI3K, high-fat diet-induced insulin resistance, or substitution 
of Thr246 by Ala. 
 
Materials and methods 
Materials. Tissue culture media were purchased from Invitrogen (Carlsbad, CA, USA). 
Rapamycin and wortmannin were obtained from Calbiochem (Darmstadt, Germany). 
Insulin and palmitic acid were obtained from Sigma Aldrich (St. Louis, MO, USA). Fatty-
acid free bovine serum albumin (BSA; fraction V) was purchased from Roche 
Biochemicals (Indianapolis, IN, USA). Palmitate was complexed to BSA by sonification (5 
min) and FBS heating (10 min; 55°C), and dissolved in DMEM (final concentration of 2% 
fatty-acid free BSA). 
Human biopsies. Muscle biopsies were obtained from 6 obese subjects with type 2 diabetes 
(4 male and 2 female subjects, duration of type 2 diabetes 8.7±1.9 years, age 59.0±1.6 
years, with fasting plasma glucose 13.1±1.3 mmol/l, HbA1c 8.1±0.6%, body weight 
100.9±5.7 kg, and BMI 35.2±1.9 kg/m2) participating in a clinical study that was approved 
by the medical ethical committee of the Leiden University Medical Center. Patients used at 
least 20 units of exogenous insulin. Four patients also used metformin and 1 patient used 
sulfonylurea derivatives. Written informed consent was obtained from the patients 
following explanation of the experimental procedures. Muscle biopsies were collected from 
the vastus lateralis muscle in the basal situation (overnight fast) and 30 min after initiation 
of a hyperinsulinaemic-euglycaemic clamp (insulin infusion rate: 40 mU/m2 per min) using 
a modified Bergström needle under localized anaesthesia with 1% lidocaine as described 
previously (38). Muscle samples were snap-frozen in liquid nitrogen-cooled isopentane and 
stored at −80°C until further analysis. 
Animals. Rat tissues were obtained from a previously published study, in which adult male 
Wistar WU rats were fed a high- or low-fat diet for 7 weeks (39;40). This investigation 
conformed to the Guide for the Care and use of Laboratory Animals, as published by the 
National Institute of Health (NIH publ. no 85-23, revised 1996) and the regulations of the 
institutional animal care and use committee. Following a 6 h fast, rats received an 
intraperitoneal injection with saline or insulin (10 U/kg body weight; Actrapid 100 U/ml; 
Novo Nordisk, Alphen aan den Rijn, The Netherlands) 30 min before being sacrificed by 
decapitation. Tissues were rapidly removed, snap frozen in liquid nitrogen-cooled 
isopentane and stored at −80°C until further analysis. 
Plasmid generation. cDNA encoding human PRAS40 (hPRAS40) was kindly provided by 
Dr. R.A. Roth (Stanford University, Stanford, CA, USA) and cloned behind a CMV 
promoter in a plasmid which also contains green fluorescent protein (GFP) behind an IRES 
(41). Via mutagenesis PCR, a stop codon was introduced at the end of the coding sequence 
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of hPRAS40, and Phe at position 129, Ser at position 183, and Thr at position 246, were 
stepwise mutated into Ala. This resulted in constructs encoding wild type hPRAS40 and 
mutant Phe129Ala-hPRAS40, Ser183Ala-hPRAS40, Thr246Ala-hPRAS40, and 
Ser183Ala/Thr246Ala-hPRAS40. All constructs were verified by sequence analysis.  
Cell culture. A14 cells are NIH3T3 fibroblasts overexpressing the human insulin receptor 
(42). L6 myoblasts were obtained from ATCC (CRL-1458), grown to confluence on α-
MEM supplemented with 10% FBS, penicillin, and streptomycin. Cells were differentiated 
into myotubes by culturing them for 7 days on α-MEM supplemented with 2% horse serum 
and antibiotics. Medium was replaced every other day. 3T3L1 adipocytes were cultured and 
differentiated into adipocytes as described previously (43). 
Transient transfections. A14 cells grown in 6-well plates were transiently transfected using 
500 ng of expression vector and Fugene 6 reagent (Roche Biochemicals, Indianapolis, IN, 
USA) as described previously (44). 
Cell incubations. Prior to insulin stimulation, 3T3L1 adipocytes and A14 fibroblasts were 
starved for 6 h on DMEM supplemented with 0.5% FBS, penicillin and streptomycin. L6 
myotubes were incubated for 4 h on αMEM containing penicillin and streptomycin. Where 
indicated, cells were pretreated with rapamycin (15 min, 100 nM), wortmannin (30 min, 
100 nM) or amino acid deprived for 30 min. For amino acid deprivation cells were 
incubated in D-PBS supplemented with MEM vitamins, glucose and pyruvate (45). Insulin 
resistance was induced by overnight incubation in DMEM containing 2% BSA and 0.38 
mM or 0.75 mM palmitate. Cells were subsequently stimulated with insulin (5 min, 100 
nM). 
Analysis of insulin signalling. Lysates from tissue biopsies or cultured cells were prepared 
as described (46), and cleared by centrifugation. Protein content was determined using a 
bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Expression and phosphorylation 
of proteins was determined by SDS-PAGE Western blotting. Antibodies against total 
PRAS40 (#2691) and phospho-specific mTOR-Ser2481 (#2974), PKB/Akt-Thr308 
(#9275), PKB/Akt-Ser473 (#4051), S6K-Thr389 (#9205) were from Cell Signalling 
Technology (Danvers, MA, USA). Antibodies against hPRAS40 (AHO1031) and phospho-
specific PRAS40-Thr246 (44-1100G) were from Invitrogen (Carlsbad, CA, USA). 
Phospho-specific antibodies against PRAS40-Ser183 were from IBL Hamburg GmBH 
(Hamburg, Germany). Antibodies against PKBβ/Akt2 (07-372) were from Upstate 
(Billerica, MA, USA). Total S6K antibody was from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Total mTOR antibody has been described (47). Bound antibodies were 
visualized by enhanced chemiluminescence and quantified by densitometry analysis of 
scanned films (Image J 1.34S; National Institutes of Health, Bethesda, MD, USA). 
Statistical analysis. Data are expressed mean ± standard error of the mean. Statistical 
analysis was performed using SPSS version 16.0. Differences between the basal and the 
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hyperinsulinaemic conditions were determined with a paired students two-tailed t-test. The 
effects of insulin and palmitate in rat tissues and cultured cell lines were determined using 





Insulin increases PRAS40-Ser183 phosphorylation both in vitro and in vivo. Incubation 
of cultured A14 fibroblasts, 3T3L1 adipocytes, and L6 myotubes for 5 min with 100 nM 
insulin increased both PRAS40-Ser183 and PRAS40-Thr246 phosphorylation (Fig. 1A). In 
skeletal muscle biopsies, a 1.5±0.1-fold increase (n=6, p<0.05) in PRAS40-Ser183 
phosphorylation was found 30 min after initiation of a hyperinsulinaemic-euglycaemic 
clamp at an infusion rate of 40 mU/m2. In line with previous findings (48;49), 
hyperinsulinaemia caused a 2.4±0.4-fold increase (n=6, p<0.05) in PRAS40-Thr246 
phosphorylation in these biopsies (Fig. 1B and 1C). Thus, insulin promotes phosphorylation 












































Figure 1. Regulation of PRAS40-Ser183 phosphorylation by insulin. A. Phosphorylation and protein expression of 
PRAS40 in A14 fibroblasts, L6 myotubes, and 3T3L1 adipocytes. Cells were kept serum-starved (-) or stimulated 
with 100 nM insulin (+) for 5 minutes. Lysates were analyzed by Western blotting with antibodies recognizing 
PRAS40 phosphorylated on Ser183 (pPRAS40-Ser183) or Thr246 (pPRAS40-Thr246), respectively. Equal loading 
was verified by reprobing the stripped filters with antibody recognizing total PRAS40. B. Phosphorylation and 
protein expression of PRAS40 in human skeletal muscle biopsies under basal conditions and 30 min after 
initiation of a hyperinsulinaemic-euglycaemic clamp. Homogenates were analyzed by Western blotting with 
antibodies recognizing PRAS40 phosphorylated on Ser183 (pPRAS40-Ser183) or Thr246 (pPRAS40-Thr246), 
respectively. Equal loading was verified by reprobing the stripped filters with antibody recognizing total PRAS40. 
C. Quantification of PRAS40 phosphorylation on Ser183 and Thr246 under basal (open bars) and 
hyperinsulinaemic-euglycaemic clamp conditions (black bars). Data are corrected for total PRAS40 protein 
expression, and are expressed as mean ± standard error of the mean (n=6). The * indicates p<0.05 as compared 
to the basal condition (paired t-test). 
Chapter 4 
 80 
Effects of amino acid starvation, rapamycin and wortmannin on insulin-mediated 
phosphorylation of PRAS40 on Ser183 and Thr246. Studies in HEK293 cells identified 
mTORC1 as the main kinase regulating PRAS40-Ser183 phosphorylation (50;51). Here, we 
assessed the importance of mTORC1 and its upstream regulators for insulin-mediated 
PRAS40 phosphorylation in insulin-sensitive A14 fibroblasts and L6 myotubes.  
In A14 fibroblasts, inhibition of PI3K using wortmannin completely abrogated the insulin-
mediated phosphorylation of PKB/Akt-Thr308, PKB/Akt-Ser473, and of the mTORC1 
substrate S6K-Thr389 (Fig. 2). The induction of PRAS40-Thr246 phosphorylation by 
insulin was almost completely prevented by wortmannin, whereas full inhibition was 
achieved for insulin-mediated PRAS40-Ser183 phosphorylation (Fig. 2). Similar results 
were obtained for L6 myotubes, although wortmannin completely prevented the insulin-
induced increases in both PRAS40-Thr246 and PRAS40-Ser183 phosphorylation in this 
cell type (Fig. 3).  
The mTORC1 inhibitor rapamycin, amino acid deprivation, or a combination of both, had 
no effect on the phosphorylation of PKB/Akt-Thr308 and PKB/Akt-Ser473, and of 
PRAS40-Thr246 in response to insulin in A14 fibroblasts (Fig. 2), but markedly inhibited 
these phosphorylations in L6 myotubes (Fig. 3). In both cell types, the insulin-mediated 
phosphorylationof mTOR-Ser2481 and of S6K-Thr389 were almost completely abolished 
by amino acid starvation and/or rapamycin treatment, indicating effective mTORC1 
inhibition (Fig. 2 and 3). Remarkably, the induction of PRAS40-Ser183 phosphorylation by 
insulin was only partially abrogated by amino acid starvation or rapamycin, and complete 
inhibition of insulin-induced PRAS40-Ser183 phosphorylation in both A14 fibroblasts and 
L6 myotubes was only observed when amino acid deprivation was combined with 
rapamycin treatment (Fig. 2 and 3). Thus, the induction of PRAS40-Ser183 by insulin is 
sensitive to inhibition of PI3K and mTORC1. However, the molecular mechanism 
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Figure 2. Effects of amino acid starvation, rapamycin, and wortmannin on insulin-mediated phosphorylation of 
PRAS40 on Ser183 and Thr246 in A14 fibroblasts. A. Serum-starved A14 fibroblasts were deprived from amino 
acids, incubated with rapamycin (15 min, 100 nM) or wortmannin (30 min, 100 nM), and stimulated with insulin 
(+) (5 min, 100 nM) or left untreated (-). Lysates were analyzed by Western blotting with antibodies recognizing 
PKB/Akt phosphorylated on Thr308 (pPKB/Akt-Thr308) or Ser473 (pPKB/Akt-erS473), PRAS40 phosphorylated 
on Ser183 (pPRAS40-Ser183) or Thr246 (pPRAS40-Thr246), mTOR phosphorylated on Ser2481 
(pmTORSer2481), and S6K phosphorylated on Thr389 (pS6K-Thr389). Equal loading was verified by reprobing 
the stripped filters with antibodies recognizing total PKB/Akt, PRAS40 and S6K, respectively. B-C. Quantification 
of PRAS40-Thr246 (B) and PRAS40-Ser183 (C) phosphorylation in A14 fibroblasts under basal (open bars) and 
insulin stimulated conditions (black bars). Data are expressed as mean + standard error of the mean (n=3). The * 
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Figure 3. Effects of amino acid starvation, rapamycin, and wortmannin on insulin-mediated phosphorylation of 
PRAS40 on Ser183 and Thr246 in L6 myotubes. Serum-starved L6 myotubes (B) were deprived from amino acids, 
incubated with rapamycin (15 min, 100 nM) or wortmannin (30 min, 100 nM), and stimulated with insulin (+) (5 
min, 100 nM) or left untreated (-). Lysates were analyzed by Western blotting with antibodies recognizing 
PKB/Akt phosphorylated on Thr308 (pPKB/Akt-Thr308) or Ser473 (pPKB/Akt-Ser473), PRAS40 phosphorylated 
on Ser183 (pPRAS40-Ser183) or Thr246 (pPRAS40-Thr246), mTOR phosphorylated on Ser2481 
(pmTORSer2481), and S6K phosphorylated on Thr389 (pS6K-Thr389). Equal loading was verified by reprobing 
the stripped filters with antibodies recognizing total PKB/Akt, PRAS40 and S6K, respectively. B-C. Quantification 
of PRAS40-Thr246 (B) and PRAS40-Ser183 (C) phosphorylation in A14 fibroblasts under basal (open bars) and 
insulin stimulated conditions (black bars). Data are expressed as mean + standard error of the mean (n=3). The * 
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Insulin resistance impairs PRAS40-Ser183 phosphorylation in response to insulin. We 
next determined the induction of PRAS40-Ser183 phosphorylation by insulin in tissues 
from control (low-fat diet; LFD) and high-fat diet (HFD) fed insulin resistant rats. 
Intraperitoneal injection of insulin increased the phosphorylation of PRAS40-Ser183 (n=3, 
p<0.05) in skeletal and cardiac muscle in LFD-fed rats (Fig. 4A-C). As previously shown 
(52), a reduced insulin-stimulated phosphorylation of PRAS40-Thr246 was evidenced in 
insulin-resistant HFD-fed rats (Fig 4A, 4D and 4E). Figure 4 shows that also the induction 
of PRAS40-Ser183 phosphorylation by insulin was markedly lower in tissues from HFD-
fed rats versus LFD-fed rats.  
In vitro, overnight incubation of A14 fibroblasts with increasing concentrations of palmitate 
induced a dose-dependent inhibition of insulin-induced phosphorylation of PKB/Akt-
Thr308 and PKB/Akt-Ser473, as well as of PRAS40-Thr246 and of the mTORC1-substrate 
S6K-Thr389 (Fig. 5A and 5B). Remarkably, whereas activation of S6K was hardly affected 
at the lowest concentration of palmitate tested, the induction of PRAS40-Ser183 
phosphorylation by insulin was completely absent (Fig. 5A and 5C). This indicates that 
activation of the mTORC1-pathway alone may not be sufficient to elicit PRAS40-Ser183 








































































































Figure 4. Phosphorylation and protein expression of PRAS40 in tissues from low- and high-fat diet fed rats. A. 
Thirty minutes before sacrifice, rats fed a low-fat diet (LFD) or high-fat diet (HFD) received an intraperitoneal 
saline (-) or insulin (+) injection. Tissue homogenates were analyzed by Western blotting with antibodies 
recognizing either PRAS40 phosphorylated on Ser183 (pPRAS40-Ser183) or Thr246 (pPRAS40-Thr246), 
respectively. Equal loading was verified by reprobing the stripped filters with antibody recognizing total PRAS40. 
B-E. Quantification of PRAS40-Ser183 phosphorylation in skeletal muscle (B) and heart (C) and PRAS40-Thr246 
phosphorylation in skeletal muscle (D) and heart (E) under basal (open bars) and insulin-stimulated conditions 
(black bars). Data are expressed as mean + standard error of the mean (n=3). The * indicates p<0.05 compared 
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Figure 5. Effects of palmitate on insulin-induced PRAS40 phosphorylation. A. A14 fibroblasts were incubated 
overnight with palmitate. Then, cells were left unstimulated (-) or stimulated with 100 nM insulin for 5 minutes 
(+). Lysates were analyzed by Western blotting with antibodies recognizing PKB/Akt phosphorylated on Thr308 
(pPKB/Akt-Thr308) or Ser473 (pPKB/Akt-Ser473), PRAS40 phosphorylated on Ser183 (pPRAS40-Ser183) or 
Thr246 (pPRAS40-Thr246), and S6K phosphorylated on Thr389 (pS6K-Thr389). Equal loading was verified by 
reprobing the stripped filters with antibodies recognizing total PKB/Akt, PRAS40 and S6K, respectively. B-C. 
Quantification of PRAS40-Thr246 (B) and PRAS40-Ser183 (C) phosphorylation in A14 fibroblasts under basal 
(open bars) and insulin stimulated conditions (black bars). Data are expressed as mean + standard error of the 
mean (n=3). The * indicates p<0.05 compared to basal conditions (independent t-test). The # indicates p<0.05 
compared 0 mM palmitate.  
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Efficient phosphorylation of PRAS40 on Ser183 requires mTORC1 binding and 
functional Thr246. The absence of insulin stimulation of PRAS40-Ser183 phosphorylation 
under conditions where insulin-mediated phosphorylation of PRAS40-Thr246 and S6K-
Thr389 are only partially inhibited, raises the possibility that phosphorylation of PRAS40-
Thr246 is required for PRAS40-Ser183 phosphorylation. To test this hypothesis, we 
compared the insulin-induced phosphorylation of overexpressed wild type human PRAS40 
(hPRAS40) with that of hPRAS40 mutants in which Phe129, Ser183 or Thr246 were 
substituted by Ala. In A14 fibroblasts expressing wild type or mutant hPRAS40, insulin 
increased the phosphorylation of PKB/Akt-Thr308 and PKB/Akt-Ser473, and of S6K-
Thr389 (Fig. 6). Insulin induced similar phosphorylation of PRAS40-Thr246 in cells 
expressing wild type, mutant Phe129Ala- or mutant Ser183Ala-hPRAS40 (Fig. 6). As 
expected, no increase in ectopic PRAS40-Thr246 phosphorylation in response to insulin 
was observed in cells transfected with mutant hPRAS40-Thr246Ala or empty vector. 
Interestingly, replacement of Thr246 by Ala lowered insulin-mediated PRAS40-Ser183 
phosphorylation to almost the same extent of mutating Phe129 to Ala, which results in a 
loss of mTORC1 binding (Fig. 6). In cells expressing mutant Ser183Ala-hPRAS40, 
phosphorylation of PRAS40-Ser183, but not of Thr246, was impaired (Fig. 6). Similar 
results for insulin-mediated PRAS40-Ser183 and PRAS40-Thr246 phosphorylation were 
obtained in L6 myotubes, and 3T3L1 adipocytes expressing the various hPRAS40 
constructs. We conclude from these data that insulin can only induce efficient 
phosphorylation of PRAS40-Ser183 when PRAS40 is bound to mTORC1 and when 
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Figure 6. Phosphorylation of PRAS40 mutants by insulin. A. A14 fibroblasts were transfected with plasmids 
encoding wild type hPRAS40 (WT), or hPRAS40 mutants in which Phe129, Ser183, or Thr246 were replaced by 
Ala (F129A, S183A, and T246A, respectively). Control cells were transfected with empty plasmid, only expressing 
green fluorescent protein (GFP). Following transfection, cells were serum-starved, and left untreated (-) or 
incubated for 5 minutes with 100 nM insulin (+). Lysates were analyzed by Western blotting with antibodies 
recognizing PKB/Akt phosphorylated on Thr308 (pPKB/Akt-Thr308) or Ser473 (pPKB/Akt-Ser473), S6K 
phosphorylated on Thr389 (pS6K-Thr389), and PRAS40 phosphorylated on Ser183 (pPRAS40-Ser183) or Thr246 
(pPRAS40-Thr246). Protein loading was verified by reprobing the stripped filters with antibodies recognizing 
total PRAS40 and GFP, respectively. B-C. Quantification of PRAS40-Thr246 (B) and PRAS40-Ser183 (C) 
phosphorylation in A14 fibroblasts under basal (open bars) and insulin stimulated conditions (black bars). Data 





PRAS40-Thr246 is among the most prominent substrates for PKB/Akt in target tissues for 
insulin action (53). The present study extends these observations by the identification of 
PRAS40-Ser183 as component of insulin action. In HEK293 cells, insulin and amino acids 
have been found to promote the phosphorylation of PRAS40-Ser183 (54;55). Here, we 
show that phosphorylation of PRAS40-Ser183 is also induced by insulin in other cell types, 
including A14 fibroblasts, L6 myotubes, and 3T3L1 adipocytes. The induction of PRAS40-
Ser183 in response to hyperinsulinaemia in vivo has not been described before. Previously, 
we demonstrated that insulin induced the phosphorylation of PRAS40-Thr246 in human 
skeletal muscle, and in various rat tissues, including the liver, the heart, skeletal muscle, 
and adipose tissue (56). In the current study, we show that the induction of PRAS40-
Thr246 phosphorylation is paralleled by the induction of PRAS40-Ser183 phosphorylation 
in skeletal and cardiac muscle. We also examined insulin-mediated PRAS40-Ser183 
phosphorylation in the liver and white adipose tissue, but non-specific bands cross-reacting 
with the phospho-specific antibody for PRAS40-Ser183 prevented a reliable interpretation 
of the immunoblots performed on lysates of these tissues. 
The signalling pathway(s) regulating insulin-induced PRAS40-Ser183 phosphorylation 
seems, depending on the cell type studied, more complex than previously assumed (57;58). 
Consistent with the insulin-mediated activation of mTORC1 via the PI3K-PKB/Akt-TSC2 
axis (59;60), the PI3K-inhibitor wortmannin prevented insulin-mediated PRAS40-Ser183 
phosphorylation. However, insulin-mediated PRAS40-Ser183 phosphorylation was only 
partially abrogated in cells expressing mutant hPRAS40-Phe129Ala, which has lost the 
ability to bind mTORC1. Furthermore, inhibition of mTORC1 in A14 fibroblasts and L6 
myotubes using either rapamycin or amino acid deprivation also only partially affected 
insulin-mediated PRAS40-Ser183 phosphorylation, whereas insulin-mediated 
phosphorylation of S6K-Thr389, another substrate for mTORC1, was completely absent. 
By contrast, in E2 cardiomyocytes, rapamycin or amino acid deprivation led to full 
inhibition of insulin-mediated PRAS40-Ser183 phosphorylation (data not shown). The 
reason for these differences in efficiency of PRAS40-Ser183 inhibition between the various 
cell types is unknown, but these data do not exclude the possibility that protein kinases 
other than mTORC1 may contribute to insulin-mediated PRAS40-Ser183 phosphorylation.  
Adding to the complexity is that insulin-mediated phosphorylation of PRAS40 on Ser183 
and Thr246 are differentially affected by palmitate. The presence of low concentrations of 
palmitate completely abrogated the insulin-mediated phosphorylation of PRAS40-Ser183, 
while only partially blunting insulin-mediated phosphorylation of PKB/Akt, and PRAS40-
Thr246. Previous studies in cell culture models for insulin resistance have shown a 
discordance in the efficiency of PKB/Akt substrate phosphorylation such that certain 
substrates are more efficiently phosphorylated than others (61). If this was the case here, 
PRAS40-Ser183 phosphorylation 
 89 
palmitate treatment should inhibit insulin-mediated activation of mTORC1 via the 
PKB/Akt substrate TSC2 more efficiently than insulin-mediated phosphorylation of 
PRAS40-Thr246 by PKB/Akt. Rather, low concentrations of palmitate that were sufficient 
to block insulin-mediated PRAS40-Ser183 phosphorylation hardly affected insulin-induced 
phosphorylation of the mTORC1-substrate S6K on Thr389. Alternatively, phosphorylation 
of PRAS40-Thr246 may be required to facilitate efficient PRAS40-Ser183 
phosphorylation. In line with this, insulin-mediated PRAS40-Ser183 phosphorylation of 
mutant hPRAS40-Thr246Ala was markedly impaired. Interestingly, neither mutant 
PRAS40-Thr246Ala nor mutant PRAS40-Ser183Ala can bind 14-3-3 proteins. It is 
however unclear whether the binding of 14-3-3 proteins to PRAS40 phosphorylated on 
Thr246, might facilitate mTORC1-binding to phosphorylate PRAS40 on Ser183. A 
comparable situation has been described for activating transcription factor 2 (ATF2), where 
efficient phosphorylation on Thr69 by low levels of c-jun N-terminal kinase (JNK) or p38 
could only be induced when ATF2 was already phosphorylated on Thr71 by extracellular-
signal-regulated kinase (ERK1/2) (61-65).  
Under conditions of insulin resistance, the insulin-mediated phosphorylation of PRAS40 on 
Thr246 and Ser183 is blunted. Phosphorylation of PRAS40 leads to dissociation from 
mTORC1 (66). Consequently, the amount of PRAS40 dissociated from mTORC1 in 
response to insulin may be lower under conditions of insulin resistance. It is not completely 
clear, however, whether this affects mTORC1 activity. Overexpression of PRAS40 has 
been found to reduce the basal phosphorylation of S6K and 4EBP1 (67-72), indicating that 
PRAS40 can function as substrate inhibitor on mTORC1. Accordingly, silencing of 
PRAS40 increases both basal and amino acid induced phosphorylation of S6K (73;74). 
However, other reports showed a lower insulin-stimulated phosphorylation of S6K and 
4EBP1 in the absence of PRAS40, suggesting that PRAS40 is also required for proper 
signalling by mTORC1 (75-77). Analysis of tissues from HFD-fed rats showed a reduced 
induction of S6K-T389 phosphorylation in response to insulin (data not shown). However, 
insulin-mediated PKB/Akt phosphorylation is also lower in tissues from HFD-fed rats 
(78;79). Therefore, it is not clear whether the reduced mTORC1 activation in response to 
insulin results from a lower phosphorylation of the PKB/Akt-TSC2 axis, a reduced 
phosphorylation and dissociation of PRAS40 from mTORC1, or both. 
In summary, this study identifies PRAS40-Ser183 as a component of insulin action. We 
showed that insulin promotes the phosphorylation of PRAS40-Ser183 both in vitro and in 
vivo. Furthermore, it was found that the induction of PRAS40-Ser183 phosphorylation was 
blunted under conditions of insulin resistance. Finally, our data indicate that 
phosphorylation of PRAS40 on Thr246 facilitates efficient phosphorylation of PRAS40-
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Alterations in signalling via protein kinase B (PKB/Akt) and mammalian target of 
rapamycin (mTOR) have been demonstrated in type 2 diabetes and human malignancies. 
Proline-rich Akt substrate of 40 kDa (PRAS40), originally identified as PKB/Akt substrate, 
has been implicated as a direct regulator of mTOR complex (mTORC) 1. Interestingly, 
phosphorylated PRAS40 has been found in the nucleus, whereas the components of the 
mTORC1 complex have a more cytosolic localisation. This raises the possibility that 
PRAS40 shuttles between the cytosol and the nucleus. In the current study, we examined 
the localisation of PRAS40 in A14 fibroblasts and rat skeletal muscle. In subcellular 
fractionation experiments, PRAS40 is predominantly found in the cytosolic fraction. Insulin 
stimulation increased the levels of phosphorylated PRAS40-Thr246 in both the cytosol and 
the nucleus of A14 fibroblasts and rat skeletal muscle. Within the PRAS40 protein, we 
identified a putative nuclear export signal (NES). Incubation of A14 fibroblasts with the 
nuclear export inhibitor leptomycin B (LMB) resulted in nuclear accumulation of 
overexpressed human PRAS40 (hPRAS40). Mutation of the NES mimicked the effects of 
LMB treatment on hPRAS40. Finally, A14 cells expressing the hPRAS40 NES-mutant 
showed increased phosphorylation of the mTORC1 substrate p70 S6 kinase (S6K) and 
PKB/Akt after insulin stimulation compared to cells expressing wild-type hPRAS40. L6 
myotubes expressing the hPRAS40 NES-mutant showed enhanced basal- and insulin-
stimulated glucose uptake. In conclusion, we have identified a NES within PRAS40, and 
nuclear accumulation of PRAS40 may sensitize insulin action mediated through PKB/Akt 
and mTORC1. 
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Introduction 
The protein kinase mammalian target of rapamycin (mTOR) is the shared catalytic subunit 
of mTOR complex 1 (mTORC1) and mTORC2 (1;2). In addition to mTOR, mTORC1 
consists of the regulatory associated protein of mTOR (raptor) and mLST8 (also known as 
Gβl) (1;2). Activation of mTORC1, which is sensitive to inhibition by rapamycin, regulates 
protein translation via phosphorylation of p70 S6 kinase (S6K) and the translation inhibitor 
eukaryotic initiation factor 4E binding protein 1 (4EBP1) (1;2). The mTORC2 complex is 
insensitive to rapamycin and contains rapamycin-insensitive companion of TOR (rictor), 
protor, mLST8 and Sin1 (1;2). Active mTORC2 has been implicated in the phosphorylation 
of the hydrophobic motif of AGC-kinases, including Ser473 of protein kinase B (PKB/Akt) 
(3;4).  
Deregulated activity of mTORC1 and PKB/Akt has been implicated in the pathogenesis of 
insulin resistance (1). Overactivation of the mTORC1/S6K-pathway in humans and rodent 
models of insulin resistance has been linked to inhibition of insulin signalling (5-10). The 
inhibition of insulin signalling is accomplished by phosphorylation on multiple serine 
residues of insulin receptor substrate 1 (IRS1), which inhibits the phosphatidylinositol 3’-
kinase (PI3K) dependent activation of PKB/Akt. 
Interestingly, a substrate of PKB/Akt, proline-rich Akt substrate of 40 kDa (PRAS40) has 
been identified as a binding partner in mTORC1 (11-15). PRAS40 directly binds to 
mTORC1 through Phe129 in its TOR signalling (TOS) motif (13-15). In response to 
extracellular stimuli, such as insulin or amino acids, PRAS40 is phosphorylated on multiple 
residues (11-13;16). These residues include the mTORC1-dependent phosphorylation of 
Ser183 and Ser221 and the PKB/Akt-mediated phosphorylation of Thr246 (15-17). After 
phosphorylation of PRAS40, the protein dissociates from mTORC1 (13-15) and binds 14-
3-3 chaperones (13;16;17).  
The function of PRAS40 within the mTORC1 complex is not completely clear. 
Overexpression of PRAS40 lowers the basal phosphorylation of S6K and 4EBP1, 
suggesting that PRAS40 can function as substrate inhibitor of mTORC1 (11-15;17). 
Accordingly, knockdown of PRAS40 enhanced phosphorylation of S6K after amino acid 
stimulation (15). However, silencing of PRAS40 has also been reported to lower insulin-
stimulated phosphorylation of S6K and 4EBP1, indicating that PRAS40 is also required for 
proper signalling by mTORC1 (13;14;17). 
The components of the mTORC1 complex are predominantly found in the cytosol, although 
individual partners can be detected in both cytosol and nucleus (18). Intriguingly, PRAS40 
was originally identified as a nuclear phosphoprotein in Hela cells (19) and staining of 
cultured cells and target tissues with phospho-specific antibodies showed nuclear 
localisation of phosphorylated PRAS40-Thr246 (20). This raises the possibility that 
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PRAS40 traffics between the cytosol and the nucleus, and that subcellular localisation of 
PRAS40 may contribute to the regulation of mTORC1 activity.  
In the current study, we examined the subcellular localisation of PRAS40 in vitro in insulin 
sensitive A14 fibroblasts and in vivo in rat skeletal muscle. We identified a nuclear export 
signal (NES) in PRAS40 and examined the functionality of the NES using the nuclear 
export inhibitor leptomycin B (LMB), and by mutation of the NES in PRAS40. Finally, we 
determined whether nuclear accumulation of PRAS40 affects the activation of PKB/Akt 
and mTORC1-signalling pathways by insulin.  
 
Materials and methods 
Materials. Tissue culture media were obtained from Invitrogen (Carlsbad, CA, USA). 
Wortmannin was purchased from Calbiochem (Darmstadt, Germany). Bovine insulin was 
purchased from Sigma Aldrich (St. Louis, MO, USA). LMB was obtained from Biomol 
international (Plymouth Meeting, PA, USA).  
Plasmid generation. cDNA encoding human PRAS40 (hPRAS40) was kindly provided by 
Dr. R.A. Roth (Stanford University, Stanford, CA, USA) and cloned behind a CMV 
promoter in a plasmid which also contains green fluorescent protein (GFP) behind an IRES 
(21). Via mutagenesis PCR, a stop codon was introduced at the end of the coding sequence 
of hPRAS40, and leucine at position 225 and 227 were mutated into alanine. This resulted 
in constructs encoding wild-type hPRAS40 and mutant L225A/L227A-hPRAS40. Both 
constructs were verified by sequence analysis. Plasmids were used for transient 
transfections or to generate lentiviruses as described (21). 
Animals. Rat skeletal muscle was obtained from a previously published study, in which 
male adult Wistar WU rats were fed a high-fat diet (HFD) or low-fat diet (LFD) for 7 
weeks (20). The investigation conformed to the guide for the care and use of laboratory 
animals, as published by the National Institute of Health (NIH publ. no 85-23, revised 
1996) and the regulations of the institutional animal care and use committee. Following a 6 
hr fast, rats received an intraperitoneal injection with saline or insulin (10 U/kg body 
weight; Actrapid 100 U/ml; Novo Nordisk, Alphen aan den Rijn, The Netherlands) 30 min 
before being sacrificed by decapitation. Skeletal muscles were rapidly removed, snap 
frozen in liquid nitrogen-cooled isopentane and stored at −80°C until further analysis. 
Cell culture. A14 cells are NIH3T3 fibroblasts overexpressing the human insulin receptor 
(22). Cells were grown on Dulbecco’s modified eagle medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), penicillin and streptomycin. L6 myoblasts were 
obtained from ATCC (CRL-1458), and were grown on α-MEM supplemented with 10% 
FBS, penicillin, and streptomycin. Prior to insulin stimulation, cells were serum starved for 
6 hrs on medium supplemented with 0.5% FBS, penicillin and streptomycin. Where 
indicated serum starvation was combined with 10 nM LMB.  
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Transient transfections. A14 cells grown in 6-well plates were transfected with 500 ng of 
expression vector using Fugene 6 reagent (Roche Biochemicals, Indianapolis, IN, USA) 
according to the manufacturer’s protocol.  
Subcellular fractionation. Nuclear proteins were extracted from A14 fibroblasts and rat 
skeletal muscle as described previously (23). Protein content was determined using the 
BCA protein assay kit. Purity of the cell fractions was checked by Western blotting, using 
antibodies against α/β-tubulin (#2148, Cell Signalling Technology, Danvers, MA, USA) 
and lamin A/C (#2032, Cell Signalling Technology, Danvers, MA, USA) as cytosolic and 
nuclear markers, respectively.  
Immunofluorescence. Immunofluorescence was carried out as described previously (20). 
In short, cells were grown on coverslips and fixed in 3.7% formaldehyde. Residual cross-
linking was quenched using NH4Cl and cells were permeabilised using 0.1% Triton X-100. 
Coverslips were blocked (0.2% BSA) and incubated overnight with hPRAS40 antibodies 
(AHO131, Invitrogen, Carlsbad, California, USA) followed by 2 h with Cy3-conjugated 
anti-mouse IgG (Jackson Immunochemicals, West Grove, PA, USA) prior to mounting 
with Vectashield containing 4’,6-diamidino-2-phenylindole (DAPI). The fluorophore-
conjugated secondary antibodies used were Cy3-conjugated anti-mouse IgG (Jackson 
Immunochemicals, West Grove, PA, USA). Pictures were taken with a CCD CoolSnap K4 
camera (Photometrics, Tucson, AZ, USA) on a Leica DM 5500 B microscope. Confocal 
pictures were taken with on a Leica TCS SP2 system using a Dm IRBE confocal 
microscope with maximal magnification. Pictures were analyzed with Leica Confocal 
Software (version 2.5).  
Analysis of insulin signalling. Cells were lysed in 100 mM Tris.HCl (pH 6.8), 3% SDS 
and 10% glycerol. Protein content was determined using a bicinchoninic acid (BCA) 
protein assay kit (Pierce, Rockford, IL, USA). Expression and phosphorylation of proteins 
was studied by SDS-PAGE and Western blotting as described (20). Antibodies against total 
PRAS40 (#2691) and phospho-specific PKB/Akt-Thr308 (#9275), PKB/Akt-Ser473 
(#4051), S6K-Thr389 (#9205) were from Cell Signalling Technology (Danvers, MA, 
USA). Antibodies against hPRAS40 (AHO1031) and phospho-specific PRAS40-Thr246 
(44-1100G) were from Invitrogen (Carlsbad, CA, USA). Phospho-specific antibodies 
against PRAS40-Ser183 were from IBL Hamburg GmBH (Hamburg, Germany). 
Antibodies against PKBβ/Akt2 (07-372) were from Upstate (Billerica, MA, USA). Total 
S6K antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Bound 
antibodies were visualized by enhanced chemiluminescence and quantified by densitometry 
analysis of scanned films (ImageJ 1.34S; National Institutes of Health, Bethesda, MD, 
USA). 
Analysis of 2-deoxyglucose uptake. Glucose uptake was performed on 12-well plates of 
differentiated L6 myotubes obtained from L6 myoblasts, which were transduced at 20% 
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confluence at an MOI of 2 with lentiviral vectors encoding either wild-type hPRAS40 or 
mutant L225A/L227A-hPRAS40 as described (21). Three days after transduction, cells 
were split, grown to confluence and differentiated into myotubes by culturing them for 7 
days on α-MEM supplemented with 2% horse serum and antibiotics. Cells were serum-
starved for 4 hrs, followed by a 45 min incubation in 50 mM HEPES, 138 mM NaCl, 1.85 
mM CaCl2, 1.3 mM MgSO4, 4.8 mM KCl (pH 7.4) at 37oC, and stimulation with insulin. 10 
minutes after the addition of insulin, 2-deoxyglucose (2-DOG) uptake was initiated by the 
addition of 0.012 µCi 2-deoxy-D[1-14C]glucose. After 10 min, the assay was terminated by 
3 washes with ice-cold phosphate-buffered saline and the addition of 1% SDS, 0.2 M 
NaOH. Incorporated radioactivity was determined by liquid scintillation counting. 
Statistical analysis. Data are expressed as mean ± SEM. Differences between groups were 
determined using the independent student’s two-tailed t-test in SPSS version 16.0. p<0.05 

























- +        - +     Insulin
Cytosol Nucleus
A
- - +      +           - - +       +    Insulin





























Figure 1. Localisation of PRAS40 in A14 fibroblasts (A) and rat skeletal muscle (B). A14 cells were serum starved 
during 6 hrs, and were left untreated (-) or stimulated with 100 nM insulin for 5 min (+). Male Wistar rats were 
put on a control low-fat diet (LFD) or high-fat diet (HFD) for 7 weeks. Following a 6 hr fast, rats received an 
intraperitoneal injection with saline or insulin (10 U/kg body weight), and were sacrificed 30 min later. Cytosolic 
and nuclear extracts from A14 fibroblasts and rat skeletal muscles were prepared as described in the experimental 
procedures. 10 μg of protein lysate was loaded on a SDS-PAGE gel. Western blot analysis was performed using 
phospho-specific antibodies against PRAS40-Thr246. Purity of the fractions was determined by reprobing the 
western blots with antibodies against tubulin and lamin A/C, respectively. Representative blots are shown of three 
independent experiments. C. Quantification of Western blots for pPRAS40-Thr246 obtained in panel B. Data are 
expressed as mean ± SEM (n=3); *: p<0.05 versus saline. 
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Results 
Subcellular localisation of PRAS40. Subcellular fractionation of A14 fibroblasts showed 
that phosphorylated PRAS40-Thr246 is predominantly localized to the cytosol (Fig. 1A). 
Insulin stimulation increased the cytosolic level of phosphorylated PRAS40-Thr246 (Fig. 
1A). Furthermore, phosphorylated PRAS40-Thr246 was detected in nuclear extracts of 
insulin-treated cells (Fig. 1A).  
We also determined the localisation of PRAS40 in vivo in skeletal muscle from control 
LFD-fed and insulin-resistant HFD-fed rats. Following subcellular fractionation, the 
cytosolic fraction of rat skeletal muscle contained phosphorylated PRAS40-Thr246 (Fig. 
1B). No differences were observed between muscles from saline-injected LFD- or HFD-fed 
rats (Fig. 1B). Insulin injection increased the level of phosphorylated PRAS40-Thr246 by 
6.5-fold in the cytosol and 3.2-fold in the nucleus of LFD-fed rats (Fig. 1B and 1C). In 
skeletal muscle from HFD-fed rats, insulin-stimulated PRAS40-Thr246 was markedly 
lower in the cytosolic fraction, and no significant nuclear accumulation of phosphorylated 




ATF2       382 V.AQLKQLLL 390
IKBA        45 MVKELQEIRL 54
Rev         75 L.PPLERLTL 83
PKIA        38 LALKLAGLDI 47
PRAS40     218 IAASMRALVL 227
B
H.sapiens 218 IAASMRALVL 227
B.taurus 218 IAASMRALVL 227
M.musculus 219 IAASMRALVL 228
R.norvegicus 219 IAASMRALVL 228
X.tropicalis 244 IAASMRALTI 253
D.rerio 314 IAASMKALLV 323
D.melanogaster 531 IAASIQALTR 540  
 
Figure 2. PRAS40 contains a nuclear export signal. A. Alignment of the nuclear export signal (NES) of PRAS40 
with the NES found in human activating transcription factor 2 (ATF2), inhibitor of nuclear factor κBα (IκBα), the 
rev protein of simian human immunodeficiency virus (rev), and cAMP-dependent protein kinase inhibitor α 
(PKIA). In the consensus sequence for the leucine-rich NES above the aligned sequences represents X any amino 
acid, and can L be substituted for by any other large hydrophobic amino acid (24). B. Alignment of the NES of 
human PRAS40 with the PRAS40 homologues from other species. 
 
PRAS40 contains a functional nuclear export signal. The presence of phosphorylated 
PRAS40-Thr246 in the nuclear fraction after insulin stimulation prompted us to analyze the 
PRAS40 protein for motifs regulating trafficking between the cytosol and the nucleus. A 10 
amino acid sequence in the carboxyterminus of the PRAS40 protein (amino acid 218-227 of 
hPRAS40), matched the sequence for a leucine-rich NES (24) (Fig. 2A). The NES in 
PRAS40 is identical between Homo sapiens, Bos taurus, Rattus norvegicus, and Mus 
musculus, slightly altered in Xenopus tropicalis and Danio rerio, and conserved to a lesser 
extent in the putative Drosophila melanogaster ortholog Lobe (Fig. 2B).  
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In order to verify the functionality of the NES, we used the nuclear export inhibitor 
leptomycin B (LMB) (25) in A14 cells expressing hPRAS40. In the absence of LMB, 
immunofluorescence labelling of A14 cells with antibodies recognizing total hPRAS40 
showed a predominant cytoplasmic localisation of hPRAS40 (Fig. 3A). Incubation with 
LMB, induced nuclear accumulation of hPRAS40 (Fig. 3A). Quantification of the 
immunofluorescence stainings using confocal microscopy showed that the percentage of 
nuclear hPRAS40 increased from 0.7% in the basal state to 22% after LMB incubation 
(Fig. 3B). Due to the broad inhibitory effect of LMB on proteins carrying a NES, we next 
mutated the NES in PRAS40 by replacing the critical leucine residues at positions 225 and 
227 by alanine (L225A/L227A). Immunofluorescent staining of A14 cells expressing 
mutant L225A/L227A-hPRAS40 showed a predominant nuclear localisation of the protein 
(Fig. 3A). Quantification of the immunofluorescence staining showed that 65% of mutant 
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Figure 3. Nuclear accumulation of hPRAS40. A. A14 fibroblasts were transfected with wild-type hPRAS40 or 
mutant L225A/L227A-hPRAS40. Transfected cells are positive for green fluorescent protein (GFP; green). Cells 
were untreated (basal) or incubated with LMB (6 hrs, 10 nM), fixed, permeabilised and incubated with anti-
hPRAS40. Bound PRAS40 antibody was visualized with anti-mouse conjugated Cy3 secondary antibodies (red). 
DNA was stained with DAPI (blue). Photographs are representative of three independent experiments. The scale 
bar equals 50 μm. B. Quantification of fluorescence detected in the nucleus and cytoplasm for the hPRAS40 
antibody in A14 cells transfected with wild-type hPRAS40 that were kept untreated (open bars), treated with LMB 
(gray bars), or transfected with mutant L225A/L227A-hPRAS40 (black bars). Data are expressed as mean ± SEM 
(n=3); *: p<0.05 versus wild-type. 
 
Nuclear accumulation of PRAS40 and insulin action. Expression of mutant L225/L227A-
hPRAS40 had no significant effect on basal phosphorylation of Ser183 and Thr246 
compared to cell expressing wild-type hPRAS40 (Figs. 4A-C). Insulin-mediated 
phosphorylation of PRAS40 on Ser183 and Thr246 showed a slight trend to be increased in 
cells expressing mutant L225A/L227A-hPRAS40 as compared to cells expressing wild-
type hPRAS40 (Figs. 4A-C). Pretreatment of cells expressing hPRAS40 with LMB also 
displayed increased phosphorylation of Ser183 and Thr246 (data not shown).  
To further investigate this point, we next determined whether nuclear accumulation of 
hPRAS40 affects insulin-induced phosphorylation of S6K on Thr389, which, like Ser183 
on PRAS40, is regulated by mTORC1 (15). Insulin stimulated phosphorylation of Thr389 
of S6K by 3.7-fold in A14 cells expressing wild-type hPRAS40 versus 4.3-fold in cells 
expressing mutant L225A/L227A-hPRAS40 (Fig. 4A/D). We also examined the insulin-
induced phosphorylation of PKB/Akt, the main kinase phosphorylating PRAS40 on 
Thr246, in cells expressing mutant L225A/L227A-hPRAS40. Insulin-induced 
phosphorylation of PKB/Akt on both Thr308 (Fig. 4A/E) and Ser473 (Fig. 4A/F) was 
slightly increased in A14 cells expressing mutant L225A/L227A-hPRAS40 when compared 
to wild-type hPRAS40. Finally, we analyzed L6 myotubes expressing wild-type or mutant 
L225A/L227A-hPRAS40 for insulin-stimulated glucose uptake. As shown in Fig. 4G, both 
basal and insulin-stimulated glucose uptake were elevated in L6 myotubes expressing 
mutant L225A/L227A-hPRAS40. Comparable data were obtained when glucose uptake 
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Figure 4. Effect of nuclear accumulation of PRAS40 on insulin action. A. Western blots of phosphorylated 
PRAS40-Thr246, PRAS40-Ser183, S6K-Thr389, PKB/Akt-Thr308, and PKB/Akt-Ser473 phosphorylation in A14 
cells transfected with wild-type hPRAS40 (WT) or mutant L225A/L227A-hPRAS40 (L225A/L227A). 24 h after 
transfection, serum-starved cells were stimulated with insulin for 5 min at 100 nM (+, filled bars) or kept 
untreated (-, open bars). B-F. Quantification of Western blots of phosphorylated PRAS40-Ser183 (B), PRAS40-
Thr246 (C), S6K-Thr389 (D), PKB/Akt-Thr308 (E), and PKB/Akt-Ser473 (F). G. Glucose uptake in L6 myotubes 
expressing wild-type or mutant L225A/L227A-hPRAS40. All data is expressed as mean ± SEM of three 




In the present study, we examined the subcellular localisation of PRAS40 in A14 
fibroblasts and rat skeletal muscle. We found that the majority of PRAS40 is localized in 
the cytoplasm and that insulin stimulation results in phosphorylated PRAS40-Thr246 in the 
nucleus in cultured A14 cells and rat skeletal muscle. Insulin-mediated nuclear 
accumulation of phosphorylated PRAS40-Thr246 was not observed in skeletal muscle from 
insulin resistant HFD-fed rats. Finally, we identified a NES within PRAS40, and forced 
accumulation of ectopic PRAS40 in the nucleus may sensitize the insulin signalling 
pathway.  
The predominant cytosolic localisation of PRAS40, which was observed in subcellular 
fractionation experiments on untransfected cells, as well as in immunofluorescence studies 
on cells transfected with hPRAS40, differs from previous immunofluorescence and 
immunohistochemistry studies using phospho-specific antibodies against PRAS40-Thr246 
(20;26;27). Staining untransfected cells with phospho-specific antibodies against PRAS40-
Ser183 also showed a predominant nuclear localisation of the endogenous phosphorylated 
PRAS40 (data not shown). The reason for discrepancy is not clear. However, since 
phosphorylated PRAS40 can interact with 14-3-3 proteins (13;16;28;29), we cannot 
exclude the possibility that the epitopes recognized by the phospho-specific PRAS40 
antibodies are masked in the cytosol when the endogenous PRAS40 protein is bound to 14-
3-3 chaperones.  
The observation that PRAS40 shuttles between the cytoplasm and the nucleus is supported 
by the presence of a functional NES, and the original identification of PRAS40 as nuclear 
phosphoprotein in Hela cells (19). The presence of phosphorylated PRAS40 in the nucleus 
of insulin-stimulated cells further substantiates the occurrence of shuttling of the PRAS40 
protein. However, we could not identify a nuclear localisation signal within the PRAS40 
sequence. Proteins smaller than 60 kDa can freely move between the cytoplasm and the 
nucleus (14) and since PRAS40 is a 40 kDa protein, it should be able to shuttle independent 
of active transport between cytoplasm and nucleus. Nevertheless, expression of hPRAS40 
in A14 cells resulted in a cytosolic localisation of the protein, while co-expression of GFP 
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resulted in both nuclear and cytosolic distribution of GFP indicating that an alternative 
mechanism may underlie the translocation of PRAS40 to the nucleus.  
A possible mechanism for nuclear import could involve the interaction of phosphorylated 
PRAS40 with 14-3-3 proteins. Multiple studies have implicated 14-3-3 proteins in the 
control of nuclear-cytosolic shuttling (30;31). Using GST pull-down experiments, we 
confirmed previous reports showing that insulin promotes the binding of PRAS40 to 14-3-3 
proteins. Interactions were observed between 14-3-3 isoforms beta, tau, eta, zeta and 
PRAS40 (data not shown) (13;16;28;29). The importance of the different phosphorylation 
sites as well as the contribution of 14-3-3 binding as chaperone for nuclear import, 
however, remains to be clarified.  
In addition to PRAS40, other components of the mTORC1 signalling pathway, like mTOR, 
raptor, TSC2, S6K, and PKB/Akt have been found in the nucleus and/or contain a NES 
(18;32-35). The function of the nuclear accumulation of these proteins is not completely 
elucidated. In the present study, nuclear accumulation of PRAS40 resulting from expression 
of mutant L225A/L227A-hPRAS40 or following incubation with LMB is associated with 
increased insulin-mediated phosphorylation of PKB/Akt (13;36). Previous reports have 
shown that neither overexpression nor silencing of PRAS40 affects the phosphorylation of 
PKB/Akt. Conversely, one study demonstrated that silencing PRAS40 abrogates insulin-
mediated phosphorylation of PKB/Akt through degradation of IRS1 (11). Although these 
contradicting findings do not exclude the possibility that PRAS40 may potentially 
contribute to the regulation of PKB/Akt, further studies are clearly required to address this 
issue.  
Interestingly, we found that forced nuclear accumulation of PRAS40 is associated with 
increased insulin-mediated phosphorylation of S6K. Previous reports have suggested that 
PRAS40 can act as substrate inhibitor of mTORC1 (11;13-15). In line with these findings, 
we also found that expression of wild-type hPRAS40 in A14 cells blunts the activation of 
S6K by insulin (data not shown). Accordingly, expression of mutant L225A/L227A-
hPRAS40, which accumulates in the nucleus, may augment the ability of mTORC1 to 
phosphorylate S6K by relieving the inhibitory constraint on mTORC1. A limitation of this 
study is that we cannot determine whether the amount of endogenous PRAS40 accumulated 
in the nucleus is sufficient to relieve the inhibitory constraint on mTORC1. We have 
estimated that approximately 3% of the total amount of Thr246-phosphorylated PRAS40 
was found in the nucleus of following insulin stimulation of rat skeletal muscle and A14 
fibroblasts (data not shown). Also, quantification of confocal images obtained from cell 
expressing wild-type hPRAS40 showed that insulin increased the amount of hPRAS40 in 
the nucleus from 0.7 to 3% (data not shown). Alternatively, PRAS40 may have a direct 
function in the nucleus. Recently, mTORC1 has been found to regulate expression of 
mitochondrial genes (37). PRAS40 as component and proposed regulator of mTORC1 
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might via this way directly influence mitochondrial gene transcription. Finally, in 
immunofluorescence studies, we observed staining of the midbody using phospho-specific 
antibodies against PRAS40-Thr246 and phospho-PRAS40-Ser183 (data not shown). Proper 
cell division is regulated through this protein complex (38). However, at this point we are 
unable to supply evidence that PRAS40 is indeed involved in the process of cell division.  
In conclusion, we have analyzed the subcellular localisation of PRAS40. Phosphorylated 
PRAS40-Thr246 has a cytosolic localisation, but after insulin stimulation phosphorylated 
PRAS40-Thr246 is detected in the nucleus of the cell. Furthermore, we identified a nuclear 
export signal in PRAS40 and observed that forced nuclear accumulation of hPRAS40 
sensitizes insulin-mediated activation of S6K. Further research and understanding of 
PRAS40 function will benefit disease knowledge linked to the PKB/Akt and mTORC1 
signalling pathway like type 2 diabetes and cancer.  
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Obesity is associated with an increased risk for the development of insulin resistance and 
type 2 diabetes mellitus. The adipose tissue is able to release free fatty acids like palmitate 
which are known factors to induce insulin resistance. At the cellular level, signalling 
through protein kinase B (PKB/Akt) and the mammalian target of rapamycin complex 1 
(mTORC1) are altered in the insulin resistant state. Proline-rich Akt substrate 40 kDa 
(PRAS40) provides a link between PKB/Akt- and mTORC1-signalling. PRAS40-Thr246 
phosphorylation is PKB/Akt dependent, while phosphorylation of PRAS40-Ser183 is 
mTORC1 dependent. Furthermore, PRAS40 has been proposed to regulate mTORC1 
activity. The current study aimed to further define the function of PRAS40 in insulin action, 
under normal conditions and following palmitate-induced insulin resistance. Incubation of 
insulin-sensitive A14 fibroblasts with palmitate reduced insulin-stimulated PKB/Akt 
phosphorylation and lowered IRS1 expression. Whereas neither silencing nor 
overexpression of PRAS40 had a significant effect on insulin signalling, the absence of 
PRAS40 worsened the impact of palmitate-induced insulin resistance by further reducing 
IRS1 expression and insulin-mediated PKB/Akt phosphorylation. Conversely, 
overexpression of human PRAS40 (hPRAS40) resulted in protection from palmitate-
induced insulin resistance when monitored at the level of PKB/Akt phosphorylation and 
IRS1 protein degradation. Finally, forced nuclear accumulation of PRAS40 through 
expression of hPRAS40 with a mutated nuclear export sequence failed to prevent palmitate-
induced inhibition of PKB/Akt phosphorylation and IRS1 protein degradation. Taken 
together our data indicate that PRAS40 protects against palmitate-induced insulin 
resistance. Furthermore, the protective effect requires a cytosolic localisation of the protein.  
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Introduction 
Obesity is highly associated with increased risk for development of insulin resistance and 
type 2 diabetes mellitus (1). Obese patients have enlarged adipose tissue secretes fatty 
acids, resulting in increased plasma free fatty acids (FFAs). FFAs are known to induce 
insulin resistance (2-4). Insulin action is initiated by binding of insulin to the insulin 
receptor (IR). The activated IR phosphorylates the insulin receptor substrate (IRS) proteins, 
which results in activation of phosphatidyl inositol 3’-kinase (PI3K) and activation of its 
downstream target protein kinase B (PKB/Akt). For full activation PKB/Akt is recruited to 
the cell membrane to become phosphorylated on Thr308 by PDK1 and on Ser473 by 
mammalian target of rapamycin complex 2 (mTORC2) (5;6). PKB/Akt has numerous 
downstream phosphorylation targets, through which PKB/Akt is a regulator of many 
metabolic functions, including glucose metabolism (7). Moreover, PKB/Akt can activate 
the mammalian target of rapamycin complex 1 (mTORC1) signalling pathway via direct 
phosphorylation of tuberous sclerosis complex (TSC) proteins. The two main downstream 
targets of mTORC1 are p70 S6 kinase (S6K) and eukaryotic translation initiation factor 4E  
binding protein (4EBP1). Through these intermediates mTOR is able to regulate cell 
growth and protein synthesis (8). Increased activity of S6K is linked to the development of 
insulin resistance via the induction of inhibitory serine phosphorylation on IRS1. Serine 
phosphorylation of IRS1 inhibits tyrosine phosphorylation by the IR, which results in 
abrogation of insulin-mediated activation of PI3K and PKB/Akt (9-13). 
Proline-rich Akt substrate of 40 kDa (PRAS40) provides a link between PKB/Akt and 
mTORC1 mediated signalling. PRAS40 has mTORC1 mediated phosphorylation sites (14-
17). The mTORC1 dependent phosphorylation sites include Ser183 and Ser221, and the 
PKB/Akt phosphorylation site is on residue Thr246 (18). Both PRAS40-Ser183 and 
PRAS40-Thr246 phosphorylation are reduced in insulin resistant rats (17;19), however the 
precise function of PRAS40 in insulin action is unclear. Some reports mention that 
silencing of PRAS40 leads to increased basal S6K phosphorylation and IRS1 degradation 
(20-23). Accordingly, overexpression of PRAS40 lowers the basal phosphorylation of S6K 
and 4EBP1. These findings suggest that PRAS40 could function as a substrate inhibitor of 
mTORC1. 
The present study aimed at detailing the function of PRAS40 in insulin action, under 
normal conditions and under conditions of insulin resistance induced by the long-chain 
fatty acid palmitate in insulin-sensitive A14 fibroblasts. Palmitate was found to abrogate 
insulin-mediated phosphorylation of PKB/Akt and PRAS40 in this cell type (17). We 
examined expression of IRS1 as well as phosphorylation of PKB/Akt and S6K in A14 cells 
under conditions of either decreased or increased PRAS40 expression and in the presence 
or absence of palmitate. Our data suggest that PRAS40 protects A14 cells against 




Materials and methods 
Materials. Tissue culture media were obtained from Invitrogen (Carlsbad, CA, USA). 
Wortmannin and rapamycin were purchased from Calbiochem (Darmstadt, Germany). 
Insulin and palmitic acid were purchased from Sigma Aldrich (St. Louis, MO, USA). 
Palmitate was complexed to 2% fatty acid-free BSA by sonification (5 min) and heating (10 
min, 55° C). Phospho-specific antibodies against PKB/Akt-Ser473 (#4051), PKB/Akt-
Thr308 (#9275), S6K-Thr389 (#9205) and total antibodies against anti-PRAS40 (#2610, 
#2691) were from Cell signalling technology (Danvers, MA, USA). Antibodies against 
Akt1 (sc-55523) and IRβ (sc-711) were from Santa Cruz biotechnology (Santa Cruz, CA, 
USA) and antibodies against Akt2 (07-372) were from Upstate (Millipore, Billerica, MA, 
USA). The polyclonal antibody against IRS1 has been described previously (24).  
Cells. A14 cells are NIH3T3 fibroblasts overexpressing the human insulin receptor (25). 
Cells were grown on Dulbecco’s Modified Eagle’s Medium (DMEM), 10% FBS, penicillin 
and streptomycin.  
Plasmid generation. Constructs expressing human PRAS40 (hPRAS40) were described 
previously (17). cDNA encoding hPRAS40 was kindly provided by Dr. R.A. Roth 
(Stanford University, Stanford, CA, USA) and cloned behind a CMV promoter (26). Via 
mutagenesis PCR, the following residues were mutated into alanine: L225 and L227. This 
resulted in plasmids expressing wild type hPRAS40 and mutant L225A/L227A-hPRAS40. 
Constructs were verified by sequence analysis. Plasmids were used for production of 
lentiviruses (26). 
For knockdown of the PRAS40 protein, the pLKO.1 lentiviral plasmids were purified from 
E. coli bacteria. Two different shRNA clones were used (TRC number: 0000198644 / CCG 
GCG ATC GTC AGA TGA GGA GAA TCT CGA GAT TCT CCT CAT CTG ACG ATC 
GTT TTT and TRC number: 0000181472 / CCG GCA ATA CCA GCG ACT TCC AGA 
ACT CGA GTT CTG GAA GTC GCT GGT ATT GTT TTT). As control SHC002 (CCG 
GCA ACA AGA TGA AGA GCA CCA ACT CGA GTT GGT GCT CTT CAT CTT GTT 
GTT TTT) was used from the mission library, which is pLKO.1 based vector carrying an 
insert that does not target human of mouse genes. Purified plasmids were used to produce 
lentiviruses (26).  
Transduction with lentiviruses. For overexpression of wild type or mutant hPRAS40 A14 
fibroblasts were transduced at 20% confluence at a MOI of 2. Three days after transduction, 
A14 cells were split and grown to confluence for experiments. For knockdown of the 
PRAS40 protein in A14 fibroblasts, cells were infected with shRNAs against PRAS40 at 
MOI of 4. 24 h after infection cells were split and grown to confluence for experiments.  
Stimulation of cells. Prior to insulin stimulation, A14 cells were starved overnight on 
DMEM supplemented with 2% fatty acid-free BSA, penicillin and streptomycin) and where 
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indicated further supplemented with 0.75 mM palmitate. Cells were subsequently 
stimulated with insulin (5 min, 100 nM).  
Analysis of insulin signalling. Cells were lysed in 100 mM Tris.HCl (pH 6.8), 3% SDS 
and 10% glycerol. Protein content was determined using a bicinchoninic acid (BCA) 
protein assay kit (Pierce, Rockford, IL, USA). Expression and phosphorylation of proteins 
was studied by SDS-PAGE and Western blotting as described (19). 
Statistical analysis. Western blots were analyzed using a two-tailed Student’s t-test in 
Microsoft Excel. p<0.05 was considered significantly different.  
 
Results 
Effects of PRAS40 knockdown on palmitate-induced insulin resistance. We started out by 
investigating the role of PRAS40 in palmitate-induced insulin resistance by examining the 
effect of PRAS40 knockdown on insulin-induced activation of insulin signalling 
intermediates. Insulin sensitive A14 fibroblasts were infected with a plasmid driving 
expression of a shRNA against PRAS40. Knockdown of PRAS40 had no significant effect 
on insulin-stimulated phosphorylation of PKB/Akt on Ser473 and Thr308 (Fig. 1A-1C). 
However, insulin-stimulated S6K-Thr389 phosphorylation was decreased after PRAS40 
knockdown (Fig. 1A & 1D). In line with a previous report (14), knockdown of PRAS40 
decreased total IRS1 protein expression (Fig. 1A & 1E) 
We used palmitate to induce insulin resistance. Incubation of A14 fibroblasts with palmitate 
was inhibited insulin-stimulated phosphorylation of PKB/Akt-Ser473 by 55%, 
phosphorylation of PKB/Akt-Thr308 by 54% and phosphorylation of S6K-Thr389 by 19% 
(Fig. 2A-2C). Furthermore, palmitate decreased IRS1 protein expression by 38% (Fig. 2D). 
After knockdown of PRAS40, palmitate deteriorated the inhibition of insulin-mediated 
phosphorylation of PKB/Akt-Ser473 to 79%, of PKB/Akt-Thr308 to 78% and of S6K-
Thr389 to 25% (Fig. 2A-2C). Knockdown of PRAS40 also further decreased IRS1 protein 






























































































































































Figure 1. PRAS40 knockdown inhibits palmitate induced insulin resistance in A14 fibroblasts. A. A14 fibroblasts 
were infected with a plasmid driving expression of a shRNA against PRAS40 (shRNA PRAS40) or a non target 
shRNA (NT). Where indicated cells were incubated overnight with 0.75 mM palmitate. Cells were left untreated or 
were insulin stimulated for 5 min at 100 nM (+). Samples were analyzed using Western blotting techniques using 
phospho-specific antibodies against PKB/Akt-Ser473, PKB/Akt-Thr308, S6K-Thr389 or antibodies against 
PRAS40, PKB/Akt, IRS1 and IRβ. B-E. Quantification of blots obtained in panel A for pPKB/Akt-Ser473 (A), 
pPKB/Akt-Thr308 (B), pS6K-Thr389 (C) and IRS1 (D). White bars indicate untreated cells, black bars indicate 
insulin stimulated cells. Data are expressed as mean + SEM and obtained from three independent experiments. *, 
p<0.05 compared to basal; $, p<0.05 compared to NT.  
 

















































































Figure 2. PRAS40 knockdown increases palmitate-induced inhibition of insulin signalling intermediates in A14 
fibroblasts. Quantifications from Fig. 1A were recalculated to express the inhibitory effect of palmitate on 
pPKB/Akt-Ser473 (A), pPKB/Akt-Thr308 (B), pS6K-Thr389 (C) and IRS1 (D). Data are expressed as mean + SEM 
and obtained from three independent experiments. $, p<0.05 compared to NT. 
 
Effects of nuclear accumulation of hPRAS40 on palmitate-induced insulin resistance. 
Since knockdown of PRAS40 worsened the inhibitory effects of palmitate on insulin 
signalling, we  next studied whether ectopic expression of hPRAS40 could reverse 
palmitate-induced insulin resistance. A14 fibroblasts were infected with a plasmid driving 
expression of hPRAS40. After the infection, we examined phosphorylation of PKB/Akt-
Ser473, PKB/Akt-Thr308, S6K-Thr389 and expression of total IRS1 (Fig. 3A). Control 
cells were infected with an empty plasmid driving expression of GFP (EV). Comparable to 
untranfected cells, in cells expressing only GFP, palmitate was able to inhibit insulin-
stimulated phosphorylation of PKB/Akt-Ser473, PKB/Akt-Thr308 and S6K-Thr389 and to 
decrease the expression of IRS1 protein. Overexpression of hPRAS40 (WT) resulted in 
diminished palmitate-induced inhibition of PKB/Akt-Ser473 and PKB/Akt-Thr308 (Fig. 3B 
& 3C). Furthermore, in cells overexpressing hPRAS40, the palmitate-induced reduction of 
IRS1 was decreased (Fig. 3E). Finally, cells infected with a plasmid driving overexpression 
of mutant L225A/L227A-hPRAS40 (NES), which accumulates in the nucleus of the cell. 
Nuclear accumulation of mutant L225A/L227A-hPRAS40 resulted in an increase in 
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Figure 3. Expression of mutant L225A/L227A-hPRAS40 is not able to protect A14 fibroblasts from palmitate-
induced insulin resistance. A. A14 cells were infected with plasmids driving expression of wild type hPRAS40 
(WT) or mutant L225A/L227A-hPRAS40 (NES). Control cells were infected with an empty plasmid driving 
expression of only expressing GFP (EV). Where indicated, cells were incubated overnight with 0.75 mM 
palmitate. Cells were left untreated (-) or were stimulated with 100 nM insulin for 5 min (+). Samples were 
analyzed with Western blotting techniques using phospho-specific antibodies against PKB/Akt-Ser473, PKB/Akt-
Thr308 and S6K-Thr389 or antibodies against PRAS40, PKB/Akt, IRS1, IRβ. Shown blots are representative of 
three independent experiments. B-E. Based on the quantifications from the blots in fig. 3A, new values were 
calculated to express the inhibitory impact of palmitate on pPKB/Akt-Ser473 (B), pPKB/Akt-Thr308 (C), pS6K-
Thr389 (D) and IRS1 (E)). Data are expressed as mean + SEM and obtained from three independent experiments. 
*, p<0.05 compared to EV. 
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Discussion 
In the present study, we have examined the role of PRAS40 in palmitate-induced insulin 
resistance. Knockdown of PRAS40 further enhanced palmitate-induced insulin resistance at 
the level of PKB/Akt-Ser473, PKB/Akt-Thr308 and IRS1. Overexpression of hPRAS40 
protected cells from palmitate-induced insulin resistance at the level of PKB/Akt-Ser473 
and IRS1. Interestingly expression of mutant nuclear accumulating L225A/L227A-
hPRAS40 was not able to protect cells from palmitate-induced insulin resistance. Palmitate 
induced insulin resistance was even enhanced at the level of PKB/Akt-Thr308 and S6K-
Thr389 in cells expressing mutant L225A/L227A-hPRAS40. This indicates that normal 
cytosolic localisation of PRAS40 is required for the protective effects of PRAS40 against 
palmitate-induced insulin resistance.  
From in vitro and in vivo studies it is known that long-chain fatty acids such as palmitate 
can induce insulin resistance. However the degree of insulin resistance depends on the 
concentration of the fatty acid, the measured output (eg. phosphorylation of PKB/Akt-
Ser473 or GLUT4 translocation) and the studied cell type. Downstream of PKB/Akt, 
PRAS40 phosphorylation was first affected by palmitate-induced insulin resistance at a 
concentration of 0.38 mM (17). Another study L6 myotubes has shown insulin resistance in 
GLUT4 translocation at a concentration of 0.15 mM palmitate, however in this case 
signalling remained intact. Only at higher concentrations, insulin resistance was evident 
when examining phosphorylation of IRS1, PKB/Akt-Ser473 and PKB/Akt-Thr308 in L6 
myotubes (27). Therefore we choose to use higher concentration of palmitate to examine 
the effect of PRAS40 on signalling. Next to insulin resistance, palmitate can induce reactive 
oxygen species (ROS), which also affect insulin signalling (28). In the present study we 
have not examined the effect of PRAS40 on ROS production for technical reasons. Since 
expression of hPRAS40 increased insulin sensitivity at the level of PKB/Akt-Ser473 and 
IRS1 (Fig. 3), we cannot exclude that PRAS40 ameliorates palmitate-mediated ROS 
production in vitro.  
Looking upstream in the insulin signalling pathway at total IRS1 protein expression, we 
observed a decrease in IRS1 protein expression after palmitate incubation or PRAS40 
knockdown (Fig. 1). In a recent article, knockdown of PRAS40 resulted in inactivation of 
IRS1 (12). In line with these findings, we observed that overexpression of hPRAS40 
resulted in IRS1 upregulation and increased phosphorylation of PKB/Akt-Ser473 and 
PKB/Akt-Thr308. We did not measure IRS1 phosphorylation, either stimulatory Ser 
phosphorylation of inhibitory Tyr phosphorylation. This information could tell us whether 
IRS1 protein activity is affected under conditions of PRAS40 knockdown. According to 
literature palmitate-induced insulin resistance is mediated via IRS1 independent 
mechanisms (27). In our cell system, phosphorylation/activity of IRS1 needs to be 
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determined first to draw a conclusion towards the role of IRS1 in palmitate-induced insulin 
resistance.  
From literature it is known, that knockdown of PRAS40 increases basal S6K-Thr389 
phosphorylation (14). However in the present study, knockdown of PRAS40 did not 
increase basal S6K-Thr389 phosphorylation (Fig. 1A & 1D). On the other hand, 
overexpression of hPRAS40 was able to decrease basal S6K phosphorylation in our cell 
system. These findings do match observations from others (14;29-31). It remains unclear 
why a decrease in S6K phosphorylation after PRAS40 knockdown was not detected in our 
cell system. Cell line specificity may be involved. More information could be acquired by 
looking at phosphorylation of S6K at different residues (eg. Thr42/Tyr424 or Ser), however 
phosphorylation of S6K-Thr389 is mostly closely related to S6K activity in vivo (32). The 
next step would be to examine activity/phosphorylation of mTORC1 itself or other 
mTORC1 substrates. 
The differences observed between wild type hPRAS40 and mutant nuclear accumulating 
L225A/L227A-hPRAS40 in the protection against palmitate-induced insulin resistance, 
indicates the importance of the nuclear export signal present in the PRAS40 protein (Fig. 
3). Within the nuclear export signal, the mTORC1 dependent PRAS40-Ser221 
phosphorylation site is present (30). It would be interesting to establish the impact of this 
phosphorylation site on palmitate-induced insulin resistance.  
In the present study, PRAS40 overexpression is able to protect A14 fibroblasts from 
palmitate-induced insulin resistance. Cytosolic localisation of the protein is of importance 
for this process. Further studies are needed to unravel the involvement of phosphorylation 
sites within the PRAS40 protein in palmitate-induced insulin resistance. And whether thus 
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Proper glucose homeostasis is important for the balanced use of energy sources, such as 
carbohydrate, amino acids and fatty acids by the human body. In addition, high circulating 
glucose concentrations are unfavourable because of the chemical reactivity of glucose with 
amino-groups in proteins. Insulin plays a critical role in maintaining adequate glucose 
levels. The intermediates involved in insulin signalling within cells are numerous and their 
specific role is not always clearly defined Within the insulin signalling cascade several 
nodes are present: the insulin receptor (IR), insulin receptor substrate (IRS) proteins, 
phosphatidyl inositol 3’-kinase (PI3K), protein kinase B (PKB/Akt), mammalian target of 
rapamycin (mTOR) and mitogen-activated protein kinase /ERK kinase (MEK) (more detail 
in reviews (1;2)). The interplay of these different nodes are responsible for proper insulin 
action. Our research focus was on phosphorylation substrates of protein kinase PKB/Akt . 
This protein kinase is able to phosphorylate Ser/Thr residues in downstream targets which 
possess the Arg-Xaa-Arg-Xaa-Xaa-pSer/pThr motif.(3;4). Through phosphorylation of 
these downstream targets, PKB/Akt is able to regulate multiple cellular processes, like 
glucose homeostasis, cell growth, apoptosis and protein synthesis. The scope of the 
presented research in this thesis was:  
1) to determine physiological PKB/Akt substrates in target tissues for insulin action;  
2) to examine alterations in expression, phosphorylation status and localisation of these 
substrates in association with conditions of insulin resistance; 
3) to search for a function of these PKB/Akt substrates. 
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PKB/Akt substrates AS160, NDRG2 and PRAS40 
With the use of the antibody recognizing the Arg-Xaa-Arg-Xaa-Xaa-pSer/pThr motif, we 
were able to study multiple PKB/Akt substrates. Increased phosphorylation of PKB/Akt 
substrate of 160 kDa (AS160) on residue Thr642 was detected in insulin stimulated rat 
liver, skeletal muscle, cardiac muscle and adipose tissue (chapter 3). Increased 
phosphorylation of AS160 was observed in biopsies from human skeletal muscle under 
conditions of hyperinsulinaemia. When the individual exhibited insulin resistance 
phosphorylation of AS160 was impaired in human skeletal muscle (5). The function of 
AS160 has been linked to GLUT4-mediated glucose uptake in skeletal muscle and adipose 
tissue (6-11). The Rab GTPase protein domain present in the AS160 protein has been found 
to be of critical importance for proper glucose uptake.  
As putative PKB/Akt substrate, we also studied N-myc downstream-regulated gene 2 
(NDRG2). The NDRG family consists of four genes (NDRG1-4). Residue Thr348 of 
NDRG2 matched the RxRxxpS/pT motif which PKB/Akt employs to phosphorylate 
downstream targets (12). In heart and skeletal muscle from insulin-stimulated rats, 
phosphorylation of NDRG2-Thr348 was increased. In liver, skeletal muscle and adipose 
tissue from insulin-stimulated mice, phosphorylation of NDRG2-Thr348 was increased. 
However different protein kinases like protein kinase C and SGK1, which are not directly 
linked to the insulin signalling pathway, are involved in phosphorylating NDRG2 (12;13). 
Further research to examine the role of NDRG2 in insulin signalling will provide us with a 
better understanding of the insulin signalling cascade. Animal models for insulin resistance 
or analysis of human biopsies comparing healthy subject to diabetic subjects could be an 
approach to answer these questions. More research has been conducted on NDRG2 in 
respect to cancer, due to the link with the oncogene myc (14).  
The most prominent substrate for PKB/Akt was found to be PRAS40. Since not much was 
known about the function of the PRAS40 protein, we decided to dedicate further research to 
this particular protein.  
 
PRAS40 as physiological PKB/Akt substrate in insulin target tissues  
Initially PRAS40 was described as a PKB/Akt substrate with a phosphorylation site at 
residue Thr246 (15). In chapter 3 we describe more in detail both in vitro and in vivo 
phosphorylation of PRAS40 on Thr246. In vitro phosphorylation is markedly diminished 
after incubation with the PI3K-inhibitor wortmannin. In E2 cardiomyocytes, 
phosphorylation of PRAS40-Thr246 is completely abolished while in A14 fibroblasts and 
L6 myotubes phosphorylation is reduced (chapters 3 & 4). These findings indicate that next 
to PKB/Akt other kinases are able to phosphorylate PRAS40 on Thr246. In agreement with 
this, PKB/Akt deficient cells showed a marked reduction in PRAS40-Thr246 
phosphorylation however not a complete abolishment of phosphorylation (15). We should 
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keep in mind that the used PKB/Akt-deficient cells were deficient for PKBα/Akt1 and 
PKBβ/Akt2, however, not for PKBγ/Akt3. PKBγ/Akt3 has been identified as PRAS40-
Thr246 phosphorylation kinase in tumorigenesis (16). However, how this relates to insulin 
signalling remains unknown. Next to PKB/Akt, the Pim kinase has been proposed as 
upstream phosphorylation kinase for PRAS40 on Thr246 (17). Also in the insulin 
producing Ins1E cells, an increase in PRAS40-Thr246 phosphorylation was detected after 
insulin stimulation (Fig. 1). In these cells, phosphorylation was PI3K dependent, since 
wortmannin was able to inhibit PRAS40-Thr246 phosphorylation. Why differences in 
phosphorylation are detected among cell types remains unclear. However, this indicates the 
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Figure 1. PRAS40-Thr246 phosphorylation in Ins1E cells is PI3K dependent. Ins1E cells were stimulated with 
insulin during the indicated times (min). Where indicated cells were pretreated with wortmannin (PI3K inhibitor), 
rapamycin (mTOR inhibitor) or U0126 (MEK inhibitor). Samples were analyzed using Western Blotting 
techniques.  
 
In chapter 4 we examined phosphorylation on Ser183, being another site within the 
PRAS40 protein which is under control of both PI3K and mTORC1. Reports in the 
literature only state the phosphorylation of Ser183 to be mTORC1 dependent (18-20). In 
these articles the PRAS40 protein was ectopically expressed and phosphorylation was 
studied using radiolabeled ATP. By introducing mutations in the PRAS40 protein we were 
able to establish the importance of the Thr246 phosphorylation site and the mTORC1-
binding site for proper phosphorylation of PRAS40 on Ser183 (chapter 4). 
 
PRAS40 phosphorylation under conditions of insulin resistance 
A clear link is present between in vivo phosphorylation of PRAS40-Thr246 and insulin 
sensitivity. In chapter 3 we describe that phosphorylation of PRAS40-Thr246 is reduced in 
the insulin resistant state. On the other hand when examining human subjects who were 
better able to control their glucose levels because of high insulin sensitivity,  we observed 
that these subjects displayed an increased phosphorylation of PRAS40-Thr246 protein in 
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skeletal muscle (21). These data suggested that PRAS40 phosphorylation may serve as a 
marker for insulin sensitivity.  
To validate this hypothesis we analysed by western blots the level of PRAS40-Thr246 
phosphorylation leukocytes from blood from diabetic patients. After comparison of two 
different patients, the phospho-specific PRAS40-Thr246 antibody displayed an additional 
band in the test subject who only received metformin and not in the test subject who 
received a combination of metformin and insulin glargin (Fig. 2). The subject on metformin 
was more insulin sensitive compared to the subject using a combination of metformin and 
insulin glargin. This might indicate that a decrease in insulin sensitivity might account for 
the loss of the additional band. With the use of a 2D approach and mass spectometry, the 
identity of the band can be determined. Isolation of leukocytes for protein analysis requires 
a specific approach, which should also be optimized prior to further research. This 
optimisation will increase the reproducibility of the experiments with human samples. 
Optimisation should include the verification whether only leukocytes have been isolated. 
With the use of flow cytometry or western blotting, the leukocyte surface marker CD45 can 
be determined to exclude the presence of other blood components. For example via a 
similar approach, detection of anion exchanger 1 will indicate the unwanted presence of 
erythrocytes in the sample. Preliminary results from isolated human leukocytes show that 
under conditions of hyperinsulinaemia, PRAS40-Thr246 phosphorylation is increased in 
time (data not shown). Further preliminary results show a correlation between PRAS40-
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Figure 2. Detection of pPRAS40-Thr246 in isolated human leukocytes. Test person received a hyperinsulinaemic 
euglycaemic clamp. During hyperinsulinaemia blood was isolated at the indicated time point (in min) after start of 
insulin infusion. Leukocytes were isolated and analyzed using Western blotting techniques. Test peson 1 received 










Function of PRAS40 in (insulin) signal transduction  
In chapter 5 we describe the presence of a nuclear export signal in the PRAS40 protein. 
Next to the phosphorylation sites, we now have a functional domain, which has as function 
to export PRAS40 from the nucleus. Opposite from export, there is import, however, how 
import of PRAS40 is mediated remains unknown. 14-3-3 proteins are known chaperones 
and could be chaperons for PRAS40 to mediate nuclear import. Experiments using 14-3-3 
fusion proteins showed an interaction of PRAS40 with 14-3-3 only after insulin stimulation 
(Fig. 3). Mutation of the nuclear export signal was able to sensitize insulin-stimulated 
PKB/Akt and S6K phosphorylation (chapter 5). In parallel mutation of the nuclear export 
signal in PRAS40 resulted in increased 14-3-3 binding under basal conditions and under 
insulin-stimulated conditions. Further research will provide more insights into the role of 
PRAS40 in the nucleus, how import of the protein is mediated and whether nuclear import 
of PRAS40 is 14-3-3 dependent. By creating a fusion protein composed of PRAS40 and a 
fluorescent protein like green fluorescent protein (GFP), experiments could be carried out 
following real-time translocation of the PRAS40 protein to the nucleus. Furthermore these 
experiments can be repeated in cells which have modified 14-3-3 levels in order to establish 
whether observed differences are thus 14-3-3 dependent. Another approach could be to 
create a 14-3-3 fusion protein with another fluorescent protein like yellow fluorescent 
protein (YFP). The combination of the 14-3-3 fusion protein and PRAS40 fusion protein 
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Figure 3. PRAS40 binding to 14-3-3. A14 cells transfected with plasmids expressing wild type or mutant 
S183A/T246A-hPRAS40or L225A/L227A-hPRAS40. After insulin stimulation cells were lysed. GST pull down was 
performed using coupled GST or GST fusion protein to 14-3-3β. Pull down and total lysates were analyzed using 




Chapter 6 describes the effects of variations in PRAS40 levels under normal conditions and 
under conditions of palmitate-induced insulin resistance. In parallel, we tried to establish a 
role for PRAS40 in palmitate-induced reactive oxygen species (ROS) production. The 
rationale behind this hypothesis is derived from the fact that increased PRAS40-Thr246 
phosphorylation is associated with increased survival of motor neurons after spinal cord 
injury (22). PRAS40-Thr246 phosphorylation was even further increased in copper/zinc-
superoxide dismutase (SOD1) transgenic animals (23). The superoxide dismutases are a 
first line of defence against superoxide produced as a byproduct of oxidative 
phosphorylation. Mammals express three different SODs: SOD1, SOD2 and extracellular 
SOD. From data presented in chapter 6 we have seen that palmitate induces insulin 
resistance. Incubation of beta cells, cardiomyocytes and isolated mitochondria with the 
monounsaturated free fatty acid oleate resulted in increased levels of ROS (24). In line with 
ROS production, oleate increases mRNA of SOD1 to counteract the production of ROS 
(25). Therefore we considered the possibility that PRAS40 has a role in palmitate-induced 
ROS production. Unfortunately knockdown of PRAS40 made the measurements for ROS 
using a fluorescent probe highly irreproducible. Time did not allow us to measure ROS 
production by other means in these experiments. So it still remains to be determined 
whether the induction of insulin resistance by fatty acids involves steps involving ROS 
production through a PRAS40-dependent pathway.  
 
 
Figure 4. Reduced induction of REDD1 protein after palmitate treatment in cells expressing mutant S183A-
hPRAS40. A. A14 cells were infected with plasmids expressing wild type hPRAS40 (WT) or mutant P129A-
hPRAS40 (P129A), S183A-hPRAS40 (S183A) or T246A-hPRAS40 (T246A). Control cells were infected with empty 
vector only expressing GFP. Cells were treated overnight with 0.75 mM palmitate and samples were analyzed 
using Western blotting techniques. B. Quantification of REDD1 blots obtained in panel A. *, p<0.05 compared to 
basal; $, p<0.05 compared to WT.  
 
In addition to the previously mentioned experiments in relation to the mechanism of  
palmitate-induced insulin resistance we examined other signalling intermediates regulating 






































14-3-3 binding protein which results in release of TSC2 and via this mechanism REDD1 is 
able to downregulate mTORC1 (26;27). After palmitate treatment we observed a significant 
increase in REDD1 expression. REDD1 expression correlated with decreased mTORC1 
signalling created by palmitate-induced insulin resistance. Expression of wild type 
hPRAS40 had no effect on the palmitate-induced increase in REDD1 protein expression. 
However, expression of mutant Ser183Ala-hPRAS40 resulted in an attenuation of the 
palmitate-induced increased expression of REDD1 (Fig. 4). This indicates that the Ser183 
of PRAS40 mediates palmitate-induced  REDD1 expression. More research on REDD1 
expression, the link with the insulin signalling pathway and PRAS40 will clarify the 
importance of these three components in palmitate-induced insulin resistance 
 
To further investigate the role of PRAS40 we also examined endothelial cells. Endothelial 
cells form the lining of blood vessels. The blood vessels ensure adequate supply of nutrients 
and oxygen to the organs of the human body. In the untreated diabetic patient, the blood 
vessels are continuously under stress due to exposure to chronically elevated plasma 
glucose levels, resulting increased risk for heart disease, diabetic retinopathy and impaired 
wound healing. Vascular endothelial growth factor (VEGF) is an important growth factor 
for endothelial cells. Especially when hypoxia develops within a tumour, VEGF is locally 
released inducing de novo vascularisation to supply the growing tumour with oxygen and 
nutrients. VEGF induces cell proliferation, migration, survival and vascular permeability 
via binding to the VEGF type 2 receptor and subsequent activation of PKB/Akt (28). 
PKB/Akt- and mTOR-activity are downregulated in human malignancies and metabolic 
disease (29-33). Hypoxia inducible factor 1α (HIF1α) expression is regulated by PI3K and 
mTOR. The stability of HIF1α is under control of oxygen and a drop in oxygen levels 
increases HIF1α levels. HIF1α has as downstream target VEGF, therefore it makes sense 
that certain tumours have elevated levels of HIF1α to ensure nutrient supply through 
vasculature to the inner tumour core.  
We thus wondered whether PRAS40 is expressed in endothelial cells and whether the 
protein plays a role in VEGF mediated signalling. PRAS40 phosphorylation was detected 
on Thr246 and Ser183 in murine b.End3 cells. Stimulation of b.End3 cells with VEGF did 
not increase PRAS40-Thr246 or PRAS40-Ser183 phosphorylation (Fig. 5). As readout for 
VEGF action we saw an increase in pERK1/2-Thr202/Tyr204 after VEGF stimulation. As 
seen in previous described cell lines, also in b.End3 cells phosphorylation of PRAS40-
Thr246 was reduced after wortmannin treatment and PRAS40-Ser183 phosphorylation was 
reduced after either wortmannin or rapamycin treatment. Unfortunately we were unable to 
detect an increase in PKB/Akt phosphorylation after VEGF stimulation in b.End3 cells, 
however, phosphorylation of mTOR downstream target S6K was prominent. Similar results 
were obtained in HUVECs and ECRFs. Next we examined the role of PRAS40 in HIF1α 
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and VEGF expression. First results displayed an increase in HIF1α and VEGF mRNA after 
PRAS40 knockdown. In the supernatant of the b.End3 cells in which PRAS40 was knocked 
down, VEGF protein levels showed a slight increase (data not shown). Further experiments 
will elucidate the impact of PRAS40 in VEGF mediated signalling. Endothelial cells 
provide a perfect cell system to study angiogenic properties. By modulating PRAS40 
protein levels through either knockdown or overexpression, endothelial cells can be used to 
study angiogenesis by seeding the cells into a matrigel matrix. In this matrix the endothelial 
cells can create tube like structures which will provide information on the role of PRAS40 
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Figure 5. PRAS40-Thr246 is regulated by PI3K, while PRAS40-Ser183 phosphorylation is regulated by PI3K and 
mTORC1 in endothelial cells. b.End3 cells were serum-starved and subsequently pretreated with wortmannin (100 
nM, 10 min) or rapamycin (100 nM, 15 min). b.End3 were left untreated (-) or stimulated with 50 ng/ml VEGF 
during 10 min (+). Samples were analyzed using Western blotting techniques. Proteins were visualized using 
phospho-specific antibodies against PRAS40-Thr246, PRAS40-Ser183, PKB/Akt-Ser473, PKB/Akt-Thr308, S6K-





Under conditions of insulin resistance, the insulin signalling hub PKB/Akt shows decreased 
activity. Many of PKB/Akt downstream phosphorylation substrates remain unknown. 
However, this thesis provides new information on PKB/Akt substrate PRAS40. PRAS40 is 
expressed in many different cell lines and cell types. With respect to signalling, PRAS40 is 
a component of both PI3K and mTORC1 mediated signalling. Different phosphorylation 
sites within the protein work together to ensure proper function of the protein. Due to the 
presence of a nuclear export signal in the protein, the ability of shuttling between the 
cytosolic and nuclear compartment is made possible. Furthermore, modification of the 
nuclear export signal or modification of expression of PRAS40 provides clear evidence that 
PRAS40 is an active player in the signalling processes controlling insulin resistance. 
Further research on PRAS40 could result in a better understanding of multiple disorders in 
which alterations in PI3K and mTORC1 mediated signalling are seen, such as in obesity, 
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De mens gebruikt suiker/glucose als brandstof om het lichaam taken te laten uitvoeren. 
Glucose komt het menselijk lichaam binnen als koolhydraat in het voedsel. Na afbraak tot 
glucose in ons spijsverteringssysteem wordt glucose door het lichaam vervoerd via het 
bloed. De bloedglucosespiegel wordt strikt gereguleerd. Het hormoon insuline is hierbij 
betrokken. Na een maaltijd stijgt de bloedsuikerspiegel. Deze stijging resulteert in afgifte 
van insuline vanuit de alvleesklier aan het bloed. Op zijn beurt stimuleert de verhoogde 
insulinespiegel de opname van glucose door spier en vetweefsel , wat als gevolg heeft dat 
de bloedsuikerspiegel weer daalt.  
Een persoon met type 2 diabetes (ook wel ouderdomssuikerziekte genoemd) heeft 
chronische verhoogde bloedsuikerspiegels. Als dit onbehandeld blijft, kan dit schadelijke 
effecten opleveren voor zenuwen en bloedvaten. Hierdoor ontstaan de zogenaamde 
diabetische complicaties als blindheid, nierfalen, voetamputaties en voortijdig sterven aan 
hart- en vaatziekten Bij type 2 diabetes is er nog wel sprake van insuline productie uit de 
alvleesklier, maar de hoeveelheid insuline is niet in staat om de bloedsuikerspiegels 
voldoende te verlagen. Dit is het gevolg van insulineresistentie van weefsels en een 
belangrijk kenmerk van deze vorm van diabetes. 
Normale insuline-werking in cellen en weefsels wordt in gang gezet door binding van 
insuline aan de bijbehorende receptor: de insuline receptor. Als gevolg van activatie van 
deze receptor, worden meerdere eiwitten in de cel actief gemaakt door er een fosfaatgroep 
aan te koppelen. Op deze wijze wordt het insulinesignaal tussen eiwitten in de cel 
doorgegeven. Insulineresistentie van de weefsels ontstaat doordat het koppelen van 
fosfaatgroepen aan eiwitten als gevolg van een insulinestimulus ontregeld is. Dat betekent 
dat wanneer insuline bindt aan de receptor, de signalen minder goed/efficiënt worden 
doorgegeven tussen de verschillende eiwitten. Uit onderzoek is gebleken dat een eiwit, 
proteïne kinase B (PKB) genaamd, onder condities van insuline resistentie minder goed 
signalen doorgeeft. Onder normale omstandigheden geeft PKB signalen aan veel andere 
eiwitten, zodat verschillende acties in het lichaam kunnen plaatsvinden. Maar als gevolg 
van insuline resistentie, functioneert PKB minder goed en zal als gevolg van deze insuline 
resistentie minder goed signalen doorgeven aan andere eiwitten. Het onderzoek beschreven 
in het proefschrift gaat over een eiwit dat geactiveerd wordt door PKB (substraat genoemd), 
maar waarvan de specifieke functie onbekend is. De naam van dit substraat is proline-rich 
PKB substrate 40 (PRAS40). Eerst hebben we gekeken of PRAS40 in weefsels die sterk 
door insuline worden aangestuurd aanwezig is en of het daarin door insuline wordt 
geactiveerd. De resultaten lieten zien dat in spierweefsel, weefsel van het hart, in de lever 
en in vetweefsel PRAS40 werd gevonden en kon worden geactiveerd door insuline. Tevens 
was er sprake van verminderde activatie van het substraat wanneer insulineresistentie van 
het weefsel aanwezig was. Door verder onderzoek waren we er ook achter gekomen dat 
PRAS40 niet op één plek, maar op meerdere plekken werd geactiveerd en dat deze 
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activaties sterk van elkaar afhankelijk waren. Verder hadden we in PRAS40 een 
gebied/domein gevonden dat locatie van PRAS40 in de cel bepaalt. Door dit domein is 
PRAS40 in staat om uit de kern te reizen. Door het kunstmatig ophopen van PRAS40 in de 
kern, zagen we dat insuline actie werd verbeterd. Dit resultaat gaf ons het vermoeden dat 
lokalisatie van PRAS40 zelf de mate van insulinewerking bepaalt (en niet dat de locatie van 
PRAS40 het gevolg is van insulinewerking). Met andere woorden: PRAS40 lijkt wel  
degelijk betrokken bij het ontstaan van insuline resistentie en dat meer PRAS40 je minder 
vatbaar maakte voor insuline resistentie.  
 
Samenvattend is het duidelijk geworden dat PRAS40 aanwezig is in vele verschillende 
weefsels en dat het geactiveerd kan worden door binding van insuline aan de receptor. 
Wanneer een persoon insuline resistent is, is dat terug te zien in verlaagde activatie van 
PRAS40. Verder weten we dat PRAS40 een beschermende rol heeft in insuline resistentie, 
maar hoe dit precies in zijn werk gaat is vooralsnog onduidelijk en dat blijft een mooi 
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Figure 2. The process of glucose dependent insulin secretion from the pancreatic β-cell. The key players in insulin 
secretion from the β-cell are glucose transporter GLUT2, glucokinase, ATP-sensitive potassium (K+) channel and 
voltage-dependent Ca2+ channel. See text for detailed description.  
 
 
Figure 3. Activation of protein kinase B (PKB/Akt) after insulin binding to the insulin receptor. For detailed 
































































































Figure 1. Regulation of mTORC1 activity by insulin, amino acids, glucose and energy deprivation. The activation 
of mTORC1 requires the binding of the small GTP-binding protein Rag and Rheb to mTORC1. The levels of GTP-
bound Rag are enhanced by amino acids. Inhibition of the activity of TSC1/TSC2 complex increases cellular 
Rheb-GTP-levels. TSC2 is regulated by phosphorylation. AMPK-mediated phosphorylation of TSC2 leads to 
activation of TSC2 and inactivation of mTORC1. Phosphorylation of PKB/Akt on its turn inactivates TSC2, thus 
increasing Rheb-GTP levels. Full activation of mTORC1 further requires the dissociation of PRAS40 from 
mTORC1, which requires phosphorylation of PRAS40 by both PKB/Akt and mTORC1. When activated, mTORC1 
regulates protein synthesis and cellular growth through phosphorylation of S6K1 and 4EBP1. Furthermore, the 




































Figure 4. Immunohistochemical staining of rat liver and cardiac ventricular tissue sections with PRAS40-Thr246 
antibody. Rats received an intraperitoneal injection with insulin 30 min before they were killed. Photographs are 
representative of four independent experiments. The scale bar indicates 25 µm 
 
 
Figure 5. Immunofluorescence staining of H9c2-E2 cardiomyocytes (A) and A14 fibroblasts (B). Cells were 
stimulated with 100 nmol/l insulin and where indicated pretreated with LY294002 (25 µmol/l, 15 min). Cells were 
fixed and stained with phospho-specific PRAS40-Thr246 antibody followed by fluorescein isothiocyanate–
conjugated anti-rabbit IgG (green) or phospho-specific PKB-Ser473 antibody followed by tetramethylrhodamine 
isothiocyanate (TRITC)-conjugated anti-mouse IgG (red). DNA was stained with DAPI (blue). Photographs are 
representative of three independent experiments 
 
























Figure 3. Nuclear accumulation of hPRAS40. A. A14 fibroblasts were transfected with wild-type hPRAS40 or 
mutant L225A/L227A-hPRAS40. Transfected cells are positive for green fluorescent protein (GFP; green). Cells 
were untreated (basal) or incubated with LMB (6 hrs, 10 nM), fixed, permeabilized and incubated with anti-
hPRAS40. Bound PRAS40 antibody was visualized with anti-mouse conjugated Cy3 secondary antibodies (red). 
DNA was stained with DAPI (blue). Photographs are representative of three independent experiments. The scale 
bar equals 50 μm. B. Quantification of fluorescence detected in the nucleus and cytoplasm for the hPRAS40 
antibody in A14 cells transfected with wild-type hPRAS40 that were kept untreated (open bars), treated with LMB 
(gray bars), or transfected with mutant L225A/L227A-hPRAS40 (black bars). Data are expressed as mean ± SEM 
(n=3); *: p<0.05 versus wild-type. 
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